10-Q 1 tfx-2018930x10q.htm 10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)
x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018
OR

¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .
Commission file number 1-5353

TELEFLEX INCORPORATED
(Exact name of registrant as specified in its charter)

Delaware |  | 23-1147939
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. employer identification no.)

550 E. Swedesford Rd., Suite 400, Wayne, PA |  | 19087
(Address of principal executive offices) |  | (Zip Code)

(610) 225-6800
(Registrant’s telephone number, including area code)
(None)
(Former Name, Former Address and Former Fiscal Year,
If Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer | x |  |  | Accelerated filer | ¨ |
Non-accelerated filer | ¨ |  |  | Smaller reporting company | ¨ |
|  |  |  | Emerging growth company | ¨ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
The registrant had 45,982,120 shares of common stock, par value $1.00 per share, outstanding as of October 30, 2018.

TELEFLEX INCORPORATED
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2018
TABLE OF CONTENTS

|  | Page
PART I — FINANCIAL INFORMATION |  |
Item 1: |  | Financial Statements (Unaudited): |  | 2
|  | Condensed Consolidated Statements of Income |  | 2
|  | Condensed Consolidated Statements of Comprehensive Income |  | 3
|  | Condensed Consolidated Balance Sheets |  | 4
|  | Condensed Consolidated Statements of Cash Flows |  | 5
|  | Condensed Consolidated Statements of Changes in Equity |  | 6
|  | Notes to Condensed Consolidated Financial Statements |  | 7
Item 2: |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 33
Item 3: |  | Quantitative and Qualitative Disclosures About Market Risk |  | 45
Item 4: |  | Controls and Procedures |  | 45
PART II — OTHER INFORMATION |  |
Item 1: |  | Legal Proceedings |  | 47
Item 1A: |  | Risk Factors |  | 47
Item 2: |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 47
Item 3: |  | Defaults Upon Senior Securities |  | 47
Item 4: |  | Mine Safety Disclosures |  | 47
Item 5: |  | Other Information |  | 47
Item 6: |  | Exhibits |  | 48
SIGNATURES |  | 49

1

PART I — FINANCIAL INFORMATION
Item 1. Financial Statements
TELEFLEX INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars and shares in thousands, except per share)
Net revenues | $ | 609,672 |  |  | $ | 534,703 |  |  | $ | 1,806,768 |  |  | $ | 1,551,197 |
Cost of goods sold | 267,099 |  |  | 239,476 |  |  | 788,147 |  |  | 710,126 |
Gross profit | 342,573 |  |  | 295,227 |  |  | 1,018,621 |  |  | 841,071 |
Selling, general and administrative expenses | 214,894 |  |  | 163,771 |  |  | 660,148 |  |  | 486,674 |
Research and development expenses | 26,365 |  |  | 21,194 |  |  | 78,410 |  |  | 59,299 |
Restructuring and impairment charges (credits) | 19,209 |  |  | (92 | ) |  | 77,625 |  |  | 13,723 |
Income from continuing operations before interest, loss on extinguishment of debt and taxes | 82,105 |  |  | 110,354 |  |  | 202,438 |  |  | 281,375 |
Interest expense | 27,171 |  |  | 21,264 |  |  | 79,763 |  |  | 58,884 |
Interest income | (320 | ) |  | (286 | ) |  | (776 | ) |  | (616 | )
Loss on extinguishment of debt | — |  |  | — |  |  | — |  |  | 5,593 |
Income from continuing operations before taxes | 55,254 |  |  | 89,376 |  |  | 123,451 |  |  | 217,514 |
(Benefit) taxes on income from continuing operations | (1,286 | ) |  | 9,978 |  |  | 14,532 |  |  | 19,404 |
Income from continuing operations | 56,540 |  |  | 79,398 |  |  | 108,919 |  |  | 198,110 |
Operating income (loss) from discontinued operations | (83 | ) |  | (3,749 | ) |  | 1,246 |  |  | (4,597 | )
Tax (benefit) on income (loss) from discontinued operations | (67 | ) |  | (1,366 | ) |  | (47 | ) |  | (1,675 | )
Income (loss) from discontinued operations | (16 | ) |  | (2,383 | ) |  | 1,293 |  |  | (2,922 | )
Net income | $ | 56,524 |  |  | $ | 77,015 |  |  | $ | 110,212 |  |  | $ | 195,188 |
Earnings per share: |  |  |  |  |  |  |
Basic: |  |  |  |  |  |  |
Income from continuing operations | $ | 1.23 |  |  | $ | 1.76 |  |  | $ | 2.39 |  |  | $ | 4.40 |
Income (loss) from discontinued operations | — |  |  | (0.05 | ) |  | 0.03 |  |  | (0.06 | )
Net income | $ | 1.23 |  |  | $ | 1.71 |  |  | $ | 2.42 |  |  | $ | 4.34 |
Diluted: |  |  |  |  |  |  |
Income from continuing operations | $ | 1.21 |  |  | $ | 1.70 |  |  | $ | 2.33 |  |  | $ | 4.24 |
Income (loss) from discontinued operations | — |  |  | (0.05 | ) |  | 0.03 |  |  | (0.06 | )
Net income | $ | 1.21 |  |  | $ | 1.65 |  |  | $ | 2.36 |  |  | $ | 4.18 |
Dividends per share | $ | 0.34 |  |  | $ | 0.34 |  |  | $ | 1.02 |  |  | $ | 1.02 |
Weighted average common shares outstanding |  |  |  |  |  |  |
Basic | 45,851 |  |  | 45,035 |  |  | 45,587 |  |  | 44,975 |
Diluted | 46,815 |  |  | 46,587 |  |  | 46,785 |  |  | 46,673 |

The accompanying notes are an integral part of the condensed consolidated financial statements.
2

TELEFLEX INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in thousands)
Net income | $ | 56,524 |  |  | $ | 77,015 |  |  | $ | 110,212 |  |  | $ | 195,188 |
Other comprehensive (loss) income, net of tax: |  |  |  |  |  |  |
Foreign currency translation, net of tax of $(3,505), $(8,429), $0, and $(26,910), for the three and nine months periods, respectively | 14,387 |  |  | 43,345 |  |  | (30,130 | ) |  | 156,012 |
Pension and other postretirement benefit plans adjustment, net of tax of $(363), $(479), $(1,253), and $(1,476) for the three and nine month period, respectively | 1,215 |  |  | 743 |  |  | 4,111 |  |  | 2,337 |
Derivatives qualifying as hedges, net of tax of $(308), $141, $(419) and $(1,029) for the three and nine month period, respectively | 1,651 |  |  | (243 | ) |  | 1,943 |  |  | 4,918 |
Other comprehensive (loss) income, net of tax: | 17,253 |  |  | 43,845 |  |  | (24,076 | ) |  | 163,267 |
Comprehensive income | $ | 73,777 |  |  | $ | 120,860 |  |  | $ | 86,136 |  |  | $ | 358,455 |

The accompanying notes are an integral part of the condensed consolidated financial statements.
3

TELEFLEX INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

| September 30, 2018 |  | December 31, 2017
| (Dollars in thousands)
ASSETS |  |  |
Current assets |  |  |
Cash and cash equivalents | $ | 356,276 |  |  | $ | 333,558 |
Accounts receivable, net | 374,341 |  |  | 345,875 |
Inventories, net | 411,066 |  |  | 395,744 |
Prepaid expenses and other current assets | 55,173 |  |  | 47,882 |
Prepaid taxes | 40,715 |  |  | 5,748 |
Assets held for sale | 3,239 |  |  | — |
Total current assets | 1,240,810 |  |  | 1,128,807 |
Property, plant and equipment, net | 421,265 |  |  | 382,999 |
Goodwill | 2,223,429 |  |  | 2,235,592 |
Intangible assets, net | 2,262,818 |  |  | 2,383,748 |
Deferred tax assets | 2,305 |  |  | 3,810 |
Other assets | 50,093 |  |  | 46,536 |
Total assets | $ | 6,200,720 |  |  | $ | 6,181,492 |
LIABILITIES AND EQUITY |  |  |
Current liabilities |  |  |
Current borrowings | $ | 77,250 |  |  | $ | 86,625 |
Accounts payable | 97,628 |  |  | 92,027 |
Accrued expenses | 105,584 |  |  | 96,853 |
Current portion of contingent consideration | 102,664 |  |  | 74,224 |
Payroll and benefit-related liabilities | 94,132 |  |  | 107,415 |
Accrued interest | 20,623 |  |  | 6,165 |
Income taxes payable | 13,347 |  |  | 11,514 |
Other current liabilities | 38,065 |  |  | 9,053 |
Total current liabilities | 549,293 |  |  | 483,876 |
Long-term borrowings | 2,075,834 |  |  | 2,162,927 |
Deferred tax liabilities | 606,082 |  |  | 603,676 |
Pension and postretirement benefit liabilities | 99,350 |  |  | 121,410 |
Noncurrent liability for uncertain tax positions | 13,170 |  |  | 12,296 |
Noncurrent contingent consideration | 141,910 |  |  | 197,912 |
Other liabilities | 208,016 |  |  | 168,864 |
Total liabilities | 3,693,655 |  |  | 3,750,961 |
Commitments and contingencies |  |  |
Total shareholders' equity | 2,507,065 |  |  | 2,430,531 |
Total liabilities and shareholders' equity | $ | 6,200,720 |  |  | $ | 6,181,492 |

The accompanying notes are an integral part of the condensed consolidated financial statements.
4

TELEFLEX INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

| Nine Months Ended
| September 30, 2018 |  | October 1, 2017
| (Dollars in thousands)
Cash flows from operating activities of continuing operations: |  |  |
Net income | $ | 110,212 |  |  | $ | 195,188 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
(Income) loss from discontinued operations | (1,293 | ) |  | 2,922 |
Depreciation expense | 44,517 |  |  | 42,390 |
Amortization expense of intangible assets | 111,974 |  |  | 63,976 |
Amortization expense of deferred financing costs and debt discount | 3,548 |  |  | 3,940 |
Loss on extinguishment of debt | — |  |  | 5,593 |
Fair value step up of acquired inventory sold | — |  |  | 10,442 |
Changes in contingent consideration | 47,344 |  |  | (109 | )
Impairment of long-lived assets | 19,110 |  |  | — |
Stock-based compensation | 16,469 |  |  | 14,519 |
Deferred income taxes, net | 8,664 |  |  | (15,682 | )
Other | (13,028 | ) |  | (13,559 | )
Changes in operating assets and liabilities, net of effects of acquisitions and disposals: |  |  |
Accounts receivable | (29,830 | ) |  | 6,428 |
Inventories | (19,665 | ) |  | (20,257 | )
Prepaid expenses and other current assets | (6,468 | ) |  | (4,009 | )
Accounts payable, accrued expenses and other liabilities | 54,581 |  |  | 24,128 |
Income taxes receivable and payable, net | (43,191 | ) |  | 3,798 |
Net cash provided by operating activities from continuing operations | 302,944 |  |  | 319,708 |
Cash flows from investing activities of continuing operations: |  |  |
Expenditures for property, plant and equipment | (55,751 | ) |  | (53,977 | )
Proceeds from sale of assets | — |  |  | 6,332 |
Payments for businesses and intangibles acquired, net of cash acquired | (22,550 | ) |  | (1,010,711 | )
Net cash used in investing activities from continuing operations | (78,301 | ) |  | (1,058,356 | )
Cash flows from financing activities of continuing operations: |  |  |
Proceeds from new borrowings | — |  |  | 1,963,500 |
Reduction in borrowings | (98,500 | ) |  | (747,576 | )
Debt extinguishment, issuance and amendment fees | (188 | ) |  | (19,114 | )
Net proceeds from share based compensation plans and the related tax impacts | 18,666 |  |  | 4,739 |
Payments for contingent consideration | (73,152 | ) |  | (245 | )
Dividends paid | (46,526 | ) |  | (45,905 | )
Net cash provided by (used in) financing activities from continuing operations | (199,700 | ) |  | 1,155,399 |
Cash flows from discontinued operations: |  |  |
Net cash used in operating activities | (701 | ) |  | (1,140 | )
Net cash used in discontinued operations | (701 | ) |  | (1,140 | )
Effect of exchange rate changes on cash and cash equivalents | (1,524 | ) |  | 58,173 |
Net increase in cash and cash equivalents | 22,718 |  |  | 473,784 |
Cash and cash equivalents at the beginning of the period | 333,558 |  |  | 543,789 |
Cash and cash equivalents at the end of the period | $ | 356,276 |  |  | $ | 1,017,573 |
Non cash investing activities of continuing operations: |  |  |
Property, plant and equipment additions due to build-to-suit lease transaction | $ | 28,147 |  |  | $ | — |
Non cash financing activities of continuing operations: |  |  |
Settlement and exchange of convertible notes with common or treasury stock | $ | — |  |  | $ | 53,207 |
Acquisition of treasury stock associated with settlement and exchange of convertible note hedge and warrant agreements | $ | 56,075 |  |  | $ | 127,158 |

The accompanying notes are an integral part of the condensed consolidated financial statements.
5

TELEFLEX INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)

| Common Stock |  | Additional Paid In Capital |  | Retained Earnings |  | Accumulated Other Comprehensive Loss |  | Treasury Stock |  | Total
| Shares |  | Dollars |  |  |  |  | Shares |  | Dollars |
| (Dollars and shares in thousands, except per share)
Balance at December 31, 2017 | 46,871 |  |  | $ | 46,871 |  |  | $ | 591,721 |  |  | $ | 2,285,886 |  |  | $ | (265,091 | ) |  | 1,704 |  |  | $ | (228,856 | ) |  | $ | 2,430,531 |
Cumulative effect adjustment resulting from the adoption of new accounting standards |  |  |  |  |  |  | 3,076 |  |  |  |  |  |  |  |  | 3,076 |
Net income |  |  |  |  |  |  |  |  | 110,212 |  |  |  |  |  |  |  |  |  |  |  | 110,212 |
Cash dividends ($1.02 per share) |  |  |  |  |  |  |  |  |  | (46,526 | ) |  |  |  |  |  |  |  |  |  |  | (46,526 | )
Other comprehensive loss |  |  |  |  |  |  |  |  |  |  |  |  | (24,076 | ) |  |  |  |  |  |  |  | (24,076 | )
Settlements of warrants |  |  |  |  | (56,115 | ) |  |  |  |  |  | (412 | ) |  | 56,075 |  |  | (40 | )
Shares issued under compensation plans | 321 |  |  | 321 |  |  | 29,315 |  |  |  |  |  |  |  |  | (47 | ) |  | 3,384 |  |  | 33,020 |
Deferred compensation |  |  |  |  |  |  | 398 |  |  |  |  |  |  |  |  | (10 | ) |  | 470 |  |  | 868 |
Balance as of September 30, 2018 | 47,192 |  |  | $ | 47,192 |  |  | $ | 565,319 |  |  | $ | 2,352,648 |  |  | $ | (289,167 | ) |  | 1,235 |  |  | $ | (168,927 | ) |  | $ | 2,507,065 |

The accompanying notes are an integral part of the condensed consolidated financial statements.
6

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1 — Basis of presentation
The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our,” “Teleflex” and the “Company”) are prepared on the same basis as its annual consolidated financial statements.
In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair presentation of financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and with Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.
In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. Accordingly, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017.
Note 2 — New accounting standards
In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. This new guidance, as amended by additional guidance issued in 2015 and 2016, is encompassed in FASB Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”) and is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and affects any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The Company adopted the new standard on January 1, 2018, applying the modified retrospective method to all of its contracts; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.2 million increase to the Company's opening balance of retained earnings on the adoption date. In addition, in connection with its adoption of the new guidance, the Company reclassified the reserve for product returns from a reduction of receivables to a liability. The reserve for returns and allowances was $4.6 million at September 30, 2018. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. Additional information and disclosures required by this new standard are contained in Note 3.
In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for leases, subject to an option to elect certain practical expedients. As a result, companies can elect to apply the transition approach either for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements or for leases existing at, or entered into after, the adoption date. The Company is currently evaluating this guidance to determine its impact on the Company’s consolidated results of operations, cash flows and financial position.
7

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The Company adopted the new standard on January 1, 2018 using the modified retrospective method of adoption; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.8 million increase to the Company's opening balance of retained earnings on the adoption date. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position.
In March 2017, the FASB issued guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. The Company adopted this guidance on January 1, 2018; the impact was not material to the consolidated financial statements.
In August 2017, the FASB issued guidance with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. The new guidance provides for changes to current designation and measurement guidance for qualifying hedging relationships and to the method of presenting hedge results. In addition, the new guidance includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The new guidance is effective for reporting periods beginning after December 15, 2018, but the guidance permits early adoptions, and the Company adopted the guidance effective October 1, 2018; the adoption did not result in any cumulative-effect adjustments to retained earnings.
In February 2018, the FASB issued new guidance to address a narrow-scope financial reporting issue that arose as a consequence of the Tax Cuts and Jobs Act ("the TCJA"). Existing guidance requires that deferred tax liabilities and assets be adjusted for a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The guidance is applicable even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income (rather than in net income), such as amounts related to benefit plans and hedging activity. As a result, the tax effects of items within accumulated other comprehensive income (referred to as stranded tax effects) do not reflect the appropriate tax rate. The new guidance permits a reclassification of these amounts from accumulated other comprehensive income to retained earnings, thereby eliminating the stranded tax effects. The new guidance also requires certain disclosures about the stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The new guidance can be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate under the TCJA is recognized. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the its consolidated results of operations, cash flows or financial position.
Note 3 - Net revenues
The Company primarily generates revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with the Company’s customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when the Company’s products are shipped from the manufacturing or distribution facility. For the Company’s OEM segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no
8

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
alternative use and the Company has an enforceable right to payment to the extent that performance has been completed. The Company markets and sells products through its direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers such as pharmacies, which comprised 86%, 10% and 4% of consolidated net revenues, respectively, for the nine months ended September 30, 2018. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice.
The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) the Company does not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service; (5) the Company classifies shipping and handling costs within cost of goods sold; and (6) with respect to the OEM segment, the Company has applied the practical expedient to exclude disclosure of remaining performance obligations as the contracts typically have a term of one year or less.
The amount of consideration the Company receives and revenue the Company recognizes varies as a result of changes in customer sales incentives, including discounts and rebates, and returns offered to customers. The estimate of revenue is adjusted upon the earlier of the following events: (i) the most likely amount of consideration expected to be received changes or (ii) the consideration becomes fixed. The Company’s policy is to accept returns only in cases in which the product is defective and covered under the Company’s standard warranty provisions. When the Company gives customers the right to return products, the Company estimates the expected returns based on an analysis of historical experience. The reserve for returns and allowances was $4.6 million and $4.4 million as of September 30, 2018 and October 1, 2017, respectively. In estimating customer rebates, the Company considers the lag time between the point of sale and the payment of the customer’s rebate claim, customer-specific trend analyses, contractual commitments, including stated rebate rates, historical experience with respect to specific customers (as the Company has a history of providing similar rebates on similar products to similar customers) and other relevant information. The reserve for customer incentive programs, including customer rebates, was $17.1 million and $10.2 million at September 30, 2018 and October 1, 2017, respectively. The Company expects the amounts subject to the reserve as of September 30, 2018 to be paid within 90 days subsequent to period-end.
9

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
The following table disaggregates revenue by global product category for the three and nine months ended September 30, 2018 and October 1, 2017.

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
Revenue by global product category (1) (2) | (Dollars in thousands)
Vascular access | $ | 142,712 |  |  | $ | 133,521 |  |  | $ | 427,557 |  |  | $ | 396,866 |
Anesthesia | 87,973 |  |  | 87,964 |  |  | 263,202 |  |  | 255,107 |
Interventional | 79,404 |  |  | 69,186 |  |  | 228,262 |  |  | 181,577 |
Surgical | 89,910 |  |  | 85,210 |  |  | 266,049 |  |  | 263,254 |
Interventional urology | 48,995 |  |  | — |  |  | 138,969 |  |  | — |
OEM | 54,838 |  |  | 48,589 |  |  | 153,286 |  |  | 137,067 |
Other (3) | 105,840 |  |  | 110,233 |  |  | 329,443 |  |  | 317,326 |
Net revenues | $ | 609,672 |  |  | $ | 534,703 |  |  | $ | 1,806,768 |  |  | $ | 1,551,197 |

(1) | The product categories listed above are presented on a global basis; in contrast, the Company’s North American reportable segments generally are defined largely based on the particular products sold by the segments, and its non-North American reportable segments are defined exclusively based on the geographic location of segment operations (with the exception of the Original Equipment and Development Services ("OEM") reportable segment, which operates globally). The Company’s EMEA and Asia reportable segments, as well as its Latin America operating segment, include net revenues from each of the product categories listed above.

(2) | The methodology used to determine the product revenues included within certain of the product categories listed in the table above differs from the methodology used to classify revenues in our reportable segments, including the similarly named North American reportable segments. The differences are due to the fact that segment classification generally is determined based on the call point within the customer's organization from which the purchase order resulting in the sale originated, while the classification of products within the product categories listed in the table above includes all sales of products within the listed product category, regardless of the call point within the customer's organization from which the sale originated.

(3) Other revenues in the table above include revenues related to sales of the Company’s respiratory, urology and cardiac products.
Note 4 — Acquisitions
On October 4, 2018, the Company acquired Essential Medical, Inc., a medical device company that developed the CE marked MANTA Vascular Closure Device, which is designed for closure of large bore arteriotomies and complements the Company's interventional product portfolio. See Note 16 for additional details.
On June 21, 2018, the Company acquired certain assets of QT Vascular LTD ("QT Vascular"), a medical device company that developed and marketed coronary balloon catheters, which complement the Company's interventional product portfolio. The aggregate consideration transferred for the assets, which primarily consisted of intellectual property, was $20.6 million. The acquisition was accounted for as a business combination.
2017 Acquisitions
During 2017, the Company completed several acquisitions; the largest of which were NeoTract, Inc. ("NeoTract") and Vascular Solutions, Inc. ("Vascular Solutions"), which are summarized below. The fair value of the consideration transferred for the 2017 acquisitions was $2.0 billion.
NeoTract
On October 2, 2017, the Company acquired NeoTract, a medical device company that developed and commercialized the UroLift System, a minimally invasive medical device for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. The Company made initial payments of $725.6 million in cash less a favorable working capital adjustment of $1.4 million. Additionally, the estimated fair value of contingent consideration related to NeoTract sales-based milestones as of September 30, 2018 was $229.4 million. The contingent consideration liability represents the estimated fair value of the Company’s obligations, under the acquisition agreement, to make additional payments of up to $300 million in the aggregate if specified sales goals through the end of 2020 are achieved. The Company made a payment of $75.0 million during 2018 as a result of the achievement of a sales goal for the period from January 1, 2018 to April 30, 2018. NeoTract financial information is primarily presented within the Interventional U
10

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
rology North America operating segment, which is included in the "all other" category in the Company's presentation of segment information.
Vascular Solutions
On February 17, 2017, the Company acquired Vascular Solutions, a medical device company that developed and marketed products for use in minimally invasive coronary and peripheral vascular procedures. The aggregate consideration paid by the Company in connection with the acquisition was $975.5 million.
Pro forma combined financial information
The following unaudited pro forma combined financial information for the three and nine months ended October 1, 2017 gives effect to the Vascular Solutions and NeoTract acquisitions as if they had occurred on January 1, 2016. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company.

| Three Months Ended |  | Nine Months Ended
| October 1, 2017 |  | October 1, 2017
| (Dollars and shares in thousands, except per share)
Net revenue | $ | 568,437 |  |  | $ | 1,660,591 |
Net income | $ | 52,909 |  |  | $ | 157,249 |
Basic earnings per common share: |  |  |
Net income | $ | 1.17 |  |  | $ | 3.50 |
Diluted earnings per common share: |  |  |
Net income | $ | 1.14 |  |  | $ | 3.37 |
Weighted average common shares outstanding: |  |  |
Basic | 45,035 |  |  | 44,975 |
Diluted | 46,587 |  |  | 46,673 |

The unaudited pro forma combined financial information presented above includes the accounting effects of the Vascular Solutions and NeoTract acquisitions, including, to the extent applicable, amortization charges from acquired intangible assets; adjustments for depreciation of property, plant and equipment; interest expense; and the related tax effects.
Note 5 — Restructuring and impairment charges (credits)
The following tables provide information regarding restructuring and impairment charges (credits) recognized by the Company for the three and nine months ended September 30, 2018 and October 1, 2017:

Three Months Ended September 30, 2018 |  |  |  |  |
| Termination benefits |  | Other costs (1) |  | Total
| (Dollars in thousands)
2018 Footprint realignment plan | $ | 1,119 |  |  | $ | 145 |  |  | $ | 1,264 |
Other restructuring programs (2) | 468 |  |  | 232 |  |  | 700 |
Restructuring charges | $ | 1,587 |  |  | $ | 377 |  |  | $ | 1,964 |
Asset impairment charges | — |  |  | 17,245 |  |  | 17,245 |
Restructuring and impairment charges | $ | 1,587 |  |  | $ | 17,622 |  |  | $ | 19,209 |

11

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)

Three Months Ended October 1, 2017 |  |  |  |  |
| Termination benefits |  | Other costs (1) |  | Total
| (Dollars in thousands)
Restructuring (credits) charges (3) | $ | (554 | ) |  | $ | 462 |  |  | $ | (92 | )

Nine Months Ended September 30, 2018 |  |  |  |  |
| Termination benefits |  | Other costs (1) |  | Total
| (Dollars in thousands)
2018 Footprint realignment plan | $ | 53,463 |  |  | $ | 275 |  |  | $ | 53,738 |
2016 Footprint realignment plan | 2,379 |  |  | 417 |  |  | 2,796 |
Other restructuring programs (4) | 1,318 |  |  | 663 |  |  | 1,981 |
Restructuring charges | $ | 57,160 |  |  | $ | 1,355 |  |  | $ | 58,515 |
Asset impairment charges | — |  |  | 19,110 |  |  | 19,110 |
Restructuring and impairment charges | $ | 57,160 |  |  | $ | 20,465 |  |  | $ | 77,625 |

Nine Months Ended October 1, 2017 |  |  |  |  |
| Termination benefits |  | Other costs (1) |  | Total
| (Dollars in thousands)
2017 Vascular Solutions integration program | $ | 4,534 |  |  | $ | 92 |  |  | $ | 4,626 |
2017 EMEA restructuring program | 5,822 |  |  | 84 |  |  | 5,906 |
2016 Footprint realignment plan | 1,099 |  |  | 233 |  |  | 1,332 |
Other restructuring programs (5) | 1,352 |  |  | 507 |  |  | 1,859 |
Restructuring charges | $ | 12,807 |  |  | $ | 916 |  |  | $ | 13,723 |

(1) | Other costs include facility closure, contract termination, and other exit costs.

(2) Other restructuring programs include the 2016 and 2014 Footprint realignment plans, the 2017 Vascular Solutions integration program, the 2017 EMEA restructuring program and the other 2016 restructuring programs.

(3) | Restructuring charges (credits) include activity related to the 2017 Vascular Solutions integration program, the 2017 EMEA restructuring program, the 2016 and 2014 footprint realignment plans, the 2017 Pyng integration program and the other 2016 restructuring programs. The Company committed to the 2017 Pyng integration program, which relates to the integration of Pyng Medical Corp. (“Pyng”) into the Company, during the second quarter of 2017, following the Company’s acquisition of Pyng in April 2017.

(4) Other restructuring programs include the 2014 Footprint realignment plan, the 2017 Vascular Solutions integration program, the 2017 EMEA restructuring program and the other 2016 restructuring programs.
(5) Other restructuring programs include the 2014 Footprint realignment plan, the 2017 Pyng integration program and the other 2016 restructuring programs.
2018 Footprint Realignment Plan
On May 1, 2018, the Company initiated a restructuring plan involving the relocation of certain European manufacturing operations to existing lower-cost locations, the outsourcing of certain of the Company’s European distribution operations and related workforce reductions (the “2018 Footprint realignment plan"). These actions are expected to be substantially completed by the end of 2024. The following table provides a summary of the Company’s cost estimates by major type of expense associated with the 2018 Footprint realignment plan:

Type of expense | Total estimated amount expected to be incurred
Termination benefits | $60 million to $70 million
Other exit costs (1) | $2 million to $4 million
Restructuring charges | $62 million to $74 million
Restructuring related charges (2) | $40 million to $59 million
Total restructuring and restructuring related charges | $102 million to $133 million

12

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)

(1) | Includes contract termination, facility closure, employee relocation, equipment relocation and outplacement costs.

(2) | Consists of pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily project management costs and costs to transfer manufacturing operations to the new locations, as well as a charge associated with the Company’s exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of the charges are expected to be recognized within costs of goods sold.

In addition to the restructuring charges shown in the tables above, the Company recorded restructuring related charges with respect to the 2018 Footprint realignment plan of $1.8 million and $2.8 million for the three and nine months ended September 30, 2018, respectively, within cost of goods sold.
As of September 30, 2018, the Company has a restructuring reserve of $51.6 million related to this plan, all of which related to termination benefits.
2016 Footprint Realignment Plan
In 2016, the Company initiated a restructuring plan (the “2016 Footprint realignment plan") involving the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. These actions commenced in the first quarter of 2016 and are expected to be substantially completed by the end of 2018.
In addition to the restructuring charges shown in the tables above, the Company recorded restructuring related charges with respect to the 2016 Footprint realignment plan of $1.7 million and $5.1 million for the three and nine months ended September 30, 2018 and $1.4 million and $5.5 million for the three and nine months ended October 1, 2017, respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations.
The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2016 Footprint realignment plan of approximately $43 million. As of September 30, 2018, the Company has incurred aggregate restructuring charges in connection with the 2016 Footprint realignment plan of $17.4 million. Additionally, as of September 30, 2018, the Company has incurred aggregate restructuring related charges of $19.8 million with respect to the 2016 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations to new locations. The restructuring related charges primarily were included in cost of goods sold. As of September 30, 2018, the Company has a restructuring reserve of $5.9 million related to this plan, all of which related to termination benefits.
2014 Footprint Realignment Plan
In 2014, the Company initiated a restructuring plan (“the 2014 Footprint realignment plan”) involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of 2020.
In addition to the restructuring charges set forth in the tables above, the Company recorded restructuring related charges with respect to the 2014 Footprint realignment plan of $0.8 million and $1.8 million for the three and nine months ended September 30, 2018, respectively, and $1.0 million and $3.1 million for the three and nine months ended October 1, 2017, respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations.
The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2014 Footprint realignment plan of $46 million to $51 million. As of September 30, 2018, the Company has incurred aggregate restructuring charges of $12.4 million in connection with the 2014 Footprint realignment plan. Additionally, as of September 30, 2018, the Company has incurred aggregate restructuring related charges of $28.7 million related to the 2014 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations from the existing locations to new locations. These restructuring related charges primarily were included in cost of goods sold. As of September 30, 2018, the Company has a restructuring reserve of $3.8 million in connection with the plan, all of which related to termination benefits.
13

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
As the restructuring programs progress, management will reevaluate the estimated expenses and charges set forth above, and may revise its estimates, as appropriate, consistent with GAAP. For additional information related to the Company's restructuring programs, see Note 4 to the Company's consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2017.
Restructuring charges (credits) by reportable operating segment, and by all other operating segments in the aggregate, for the three and nine months ended September 30, 2018 and October 1, 2017 are set forth in the following table:

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in thousands)
Vascular North America | $ | 203 |  |  | $ | 582 |  |  | $ | 725 |  |  | $ | 1,663 |
Interventional North America | (26 | ) |  | (228 | ) |  | 881 |  |  | 4,178 |
Anesthesia North America | 38 |  |  | 220 |  |  | 164 |  |  | 1,031 |
EMEA | 1,520 |  |  | (632 | ) |  | 54,310 |  |  | 6,483 |
All other | 229 |  |  | (34 | ) |  | 2,435 |  |  | 368 |
Restructuring charges | $ | 1,964 |  |  | $ | (92 | ) |  | $ | 58,515 |  |  | $ | 13,723 |

Asset Impairment Charges
During the third quarter 2018, the Company decided to abandon certain intellectual property and other assets associated with products that will be eliminated from the Company's interventional product portfolio. As a result, the Company recognized pre-tax impairment charges of $17.2 million ($9.2 million after tax) for the three months ended September 30, 2018.
Note 6 — Inventories, net
Inventories as of September 30, 2018 and December 31, 2017 consisted of the following:

| September 30, 2018 |  | December 31, 2017
| (Dollars in thousands)
Raw materials | $ | 105,600 |  |  | $ | 98,451 |
Work-in-process | 65,291 |  |  | 62,381 |
Finished goods | 240,175 |  |  | 234,912 |
Inventories, net | $ | 411,066 |  |  | $ | 395,744 |

Note 7 — Goodwill and other intangible assets, net
The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment, and by all other operating segments in the aggregate, for the nine months ended September 30, 2018:

| Vascular North America |  | Interventional North America |  | Anesthesia North America |  | Surgical North America |  | EMEA |  | Asia |  | OEM |  | All Other |  | Total
| (Dollars in thousands)
December 31, 2017 | $ | 264,869 |  |  | $ | 433,049 |  |  | $ | 157,289 |  |  | $ | 250,912 |  |  | $ | 494,548 |  |  | $ | 209,200 |  |  | $ | 4,883 |  |  | $ | 420,842 |  |  | $ | 2,235,592 |
Goodwill related to acquisitions | — |  |  | 1,027 |  |  | — |  |  | — |  |  | (27 | ) |  | (9 | ) |  | — |  |  | (413 | ) |  | 578 |
Currency translation adjustment | — |  |  | (1,934 | ) |  | (634 | ) |  | — |  |  | (7,778 | ) |  | (3,079 | ) |  | — |  |  | 684 |  |  | (12,741 | )
September 30, 2018 | $ | 264,869 |  |  | $ | 432,142 |  |  | $ | 156,655 |  |  | $ | 250,912 |  |  | $ | 486,743 |  |  | $ | 206,112 |  |  | $ | 4,883 |  |  | $ | 421,113 |  |  | $ | 2,223,429 |

14

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
The Company's gross carrying amount of, and accumulated amortization relating to, intangible assets as of September 30, 2018 and December 31, 2017 were as follows:

| Gross Carrying Amount |  | Accumulated Amortization
| September 30, 2018 |  | December 31, 2017 |  | September 30, 2018 |  | December 31, 2017
| (Dollars in thousands)
Customer relationships | $ | 1,020,603 |  |  | $ | 1,023,837 |  |  | $ | (314,051 | ) |  | $ | (281,263 | )
In-process research and development | 29,377 |  |  | 34,672 |  |  | — |  |  | — |
Intellectual property | 1,273,503 |  |  | 1,287,487 |  |  | (305,350 | ) |  | (258,580 | )
Distribution rights | 23,637 |  |  | 23,697 |  |  | (17,756 | ) |  | (16,996 | )
Trade names | 569,570 |  |  | 571,510 |  |  | (33,001 | ) |  | (22,069 | )
Non-compete agreements | 23,672 |  |  | 23,429 |  |  | (7,386 | ) |  | (1,976 | )
| $ | 2,940,362 |  |  | $ | 2,964,632 |  |  | $ | (677,544 | ) |  | $ | (580,884 | )

During the third quarter 2018, the Company recognized a $16.9 million pre-tax ($8.9 million after tax) impairment charge related to the abandonment of certain intellectual property intangible assets. Refer to Note 5 for additional details.
Note 8 — Financial instruments
On October 4, 2018, the Company executed cross-currency interest rate swaps to hedge against the effect of variability in the U.S. dollar to euro exchange rate. See Note 16 for additional details.
Foreign Currency Forward Contracts
The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage exposure related to foreign currency transactions. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. For the three and nine months ended September 30, 2018 the Company recognized a gain related to non-designated foreign currency forward contracts of $1.0 million and $0.3 million, respectively. For the three and nine months ended October 1, 2017, the Company recognized a loss related to non-designated foreign currency forward contracts of $0.6 million and $3.7 million, respectively.
The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of September 30, 2018 and December 31, 2017:

| September 30, 2018 |  | December 31, 2017
| Fair Value
| (Dollars in thousands)
Asset derivatives: |  |  |
Designated foreign currency forward contracts | $ | 2,158 |  |  | $ | 914 |
Non-designated foreign currency forward contracts | 175 |  |  | 307 |
Prepaid expenses and other current assets | $ | 2,333 |  |  | $ | 1,221 |
Total asset derivatives | $ | 2,333 |  |  | $ | 1,221 |
Liability derivatives: |  |  |
Designated foreign currency forward contracts | $ | 572 |  |  | $ | 1,373 |
Non-designated foreign currency forward contracts | 1,064 |  |  | 53 |
Other current liabilities | $ | 1,636 |  |  | $ | 1,426 |
Total liability derivatives | $ | 1,636 |  |  | $ | 1,426 |

15

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of September 30, 2018 and December 31, 2017 was $127.5 million and $88.5 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of September 30, 2018 and December 31, 2017 was $124.6 million and $110.6 million, respectively. All open foreign currency forward contracts as of September 30, 2018 have durations of twelve months or less.
There was no ineffectiveness related to the Company’s cash flow hedges during the three and nine months ended September 30, 2018 and October 1, 2017.
Concentration of Credit Risk
Concentrations of credit risk with respect to trade accounts receivable are generally limited due to the Company’s large number of customers and their diversity across many geographic areas. However, a portion of the Company’s trade accounts receivable outside the United States include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the creditworthiness of the healthcare systems in those countries and the financial stability of those countries' economies.
Certain of the Company’s customers, particularly in Greece, Italy, Spain and Portugal, have extended or delayed payments for products and services already provided, raising collectability concerns regarding the Company’s accounts receivable from these customers. As a result, the Company continues to closely monitor the allowance for doubtful accounts with respect to these customers. The following table provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at September 30, 2018 and December 31, 2017:

| September 30, 2018 |  | December 31, 2017
| (Dollars in thousands)
Allowance for doubtful accounts (1) | $ | 9,657 |  |  | $ | 10,255 |
Current and long-term trade accounts receivable, net in Greece, Italy, Spain and Portugal (2) | $ | 51,468 |  |  | $ | 49,054 |
Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal | 14.1 | % |  | 14.6 | %

(1) The current portion of the allowance for doubtful accounts was $3.9 million and $3.5 million as of September 30, 2018 and December 31, 2017, respectively, and was recognized in accounts receivable, net.

(2) | The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at September 30, 2018 and December 31, 2017 was $4.2 million and $3.3 million, respectively.

For the nine months ended September 30, 2018 and October 1, 2017, net revenues from customers in Greece, Italy, Spain and Portugal were $107.7 million and $96.0 million, respectively.
Note 9 — Fair value measurement
For a description of the fair value hierarchy, see Note 10 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017.
The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017:

| Total carrying value at September 30, 2018 |  | Quoted prices in active markets (Level 1) |  | Significant other observable Inputs (Level 2) |  | Significant unobservable Inputs (Level 3)
| (Dollars in thousands)
Investments in marketable securities | $ | 9,849 |  |  | $ | 9,849 |  |  | $ | — |  |  | $ | — |
Derivative assets | 2,333 |  |  | — |  |  | 2,333 |  |  | — |
Derivative liabilities | 1,636 |  |  | — |  |  | 1,636 |  |  | — |
Contingent consideration liabilities | 244,574 |  |  | — |  |  | — |  |  | 244,574 |

16

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)

| Total carrying value at December 31, 2017 |  | Quoted prices in active markets (Level 1) |  | Significant other observable Inputs (Level 2) |  | Significant unobservable Inputs (Level 3)
| (Dollars in thousands)
Investments in marketable securities | $ | 9,045 |  |  | $ | 9,045 |  |  | $ | — |  |  | $ | — |
Derivative assets | 1,221 |  |  | — |  |  | 1,221 |  |  | — |
Derivative liabilities | 1,426 |  |  | — |  |  | 1,426 |  |  | — |
Contingent consideration liabilities | 272,136 |  |  | — |  |  | — |  |  | 272,136 |

There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the nine months ended September 30, 2018.
Valuation Techniques
The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices.
The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses foreign currency forward contracts to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. The Company measures the fair value of the foreign currency forward contracts by calculating the amount required to enter into offsetting contracts with similar remaining maturities as of the measurement date, based on quoted market prices, and taking into account the creditworthiness of the counterparties.
The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions, which are discussed immediately below.
Contingent consideration
As of September 30, 2018, the Company estimates that contingent consideration payments will occur in 2018 through 2029, and the maximum amount of undiscounted payments the Company could make under contingent consideration arrangements is $325 million. The contingent consideration liabilities, which primarily consist of Company obligations payable if specified net sales goals are achieved, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and projected payment dates.
The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The contingent consideration liability related to the NeoTract acquisition represents the estimated fair value of the Company's obligations to make additional payments of up to $300 million in the aggregate if specified sales goals are achieved. Specifically, the payments are based on net sales (as defined in the NeoTract acquisition agreement) for the years ended December 31, 2018, 2019 and 2020. The fair value of the contingent consideration related to the NeoTract acquisition was estimated using a Monte Carlo valuation approach, which simulates future revenues during the earn out-period using management's best estimates. The Company determines the value of its other contingent consideration liabilities based on a probability-weighted discounted cash flow analysis. Increases in projected revenues and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates may result in significantly lower fair value measurements; decreases in the discount rates may have the opposite effect.
17

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration recognized in connection with the NeoTract acquisition.

| Valuation Technique |  | Unobservable Input |  | Range
Contingent consideration | Monte Carlo simulation |  | Revenue volatility |  | 24.1 | %
|  |  | Risk free rate |  | Cost of debt structure |
|  |  | Projected year of payment |  | 2019 - 2021 |

The following table provides information regarding changes, during the nine months ended September 30, 2018, in Level 3 financial liabilities related to contingent consideration:

| Contingent consideration
| 2018
| (Dollars in thousands)
Balance - December 31, 2017 | $ | 272,136 |
Additions (1) | 396 |
Payments (2) | (75,252 | )
Revaluations | 47,344 |
Translation adjustment | (50 | )
Balance - September 30, 2018 | $ | 244,574 |

(1) The Company established a liability related to the estimated fair value of contingent consideration associated with the acquired assets from QT Vascular.
(2) Consists mainly of a $75.0 million payment resulting from the achievement of a sales goal associated with the NeoTract acquisition for the period from January 1, 2018 to April 30, 2018.
Note 10 — Shareholders’ equity
Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding:

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Shares in thousands)
Basic | 45,851 |  |  | 45,035 |  |  | 45,587 |  |  | 44,975 |
Dilutive effect of share-based awards | 919 |  |  | 934 |  |  | 1,007 |  |  | 873 |
Dilutive effect of convertible notes and warrants | 45 |  |  | 618 |  |  | 191 |  |  | 825 |
Diluted | 46,815 |  |  | 46,587 |  |  | 46,785 |  |  | 46,673 |

The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.7 million for the three and nine months ended September 30, 2018 and 0.6 million for the three and nine months ended October 1, 2017.
In connection with the issuance by the Company in 2010 of $400 million principal amount of convertible notes that matured in August 2017, and as part of hedging arrangements between the Company and two institutional counterparties, the Company issued warrants to the counterparties, entitling them to purchase Company common stock. These transactions are described in greater detail in Note 11 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017. At September 30, 2018, all of the warrants either (a) were canceled as a result of warrant unwind agreements between the Company and the counterparties or (b) were exercised by the counterparties.
18

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2018 and October 1, 2017:

| Cash Flow Hedges |  | Pension and Other Postretirement Benefit Plans |  | Foreign Currency Translation Adjustment |  | Accumulated Other Comprehensive (Loss) Income
| (Dollars in thousands)
Balance as of December 31, 2017 | $ | 340 |  |  | $ | (138,808 | ) |  | $ | (126,623 | ) |  | $ | (265,091 | )
Other comprehensive income (loss) before reclassifications | 2,816 |  |  | 127 |  |  | (30,130 | ) |  | (27,187 | )
Amounts reclassified from accumulated other comprehensive income | (873 | ) |  | 3,984 |  |  | — |  |  | 3,111 |
Net current-period other comprehensive income (loss) | 1,943 |  |  | 4,111 |  |  | (30,130 | ) |  | (24,076 | )
Balance as of September 30, 2018 | $ | 2,283 |  |  | $ | (134,697 | ) |  | $ | (156,753 | ) |  | $ | (289,167 | )

| Cash Flow Hedges |  | Pension and Other Postretirement Benefit Plans |  | Foreign Currency Translation Adjustment |  | Accumulated Other Comprehensive (Loss) Income
| (Dollars in thousands)
Balance as of December 31, 2016 | $ | (2,424 | ) |  | $ | (136,596 | ) |  | $ | (299,697 | ) |  | $ | (438,717 | )
Other comprehensive (loss) before reclassifications | 3,383 |  |  | (1,050 | ) |  | 156,012 |  |  | 158,345 |
Amounts reclassified from accumulated other comprehensive loss | 1,535 |  |  | 3,387 |  |  | — |  |  | 4,922 |
Net current-period other comprehensive income | 4,918 |  |  | 2,337 |  |  | 156,012 |  |  | 163,267 |
Balance as of October 1, 2017 | $ | 2,494 |  |  | $ | (134,259 | ) |  | $ | (143,685 | ) |  | $ | (275,450 | )

The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and nine months ended September 30, 2018 and October 1, 2017:

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in thousands)
(Gains) losses on foreign exchange contracts: |  |  |  |  |  |  |
Cost of goods sold | $ | (87 | ) |  | $ | (1,179 | ) |  | $ | (1,038 | ) |  | $ | 1,769 |
Total before tax | (87 | ) |  | (1,179 | ) |  | (1,038 | ) |  | 1,769 |
Taxes (benefit) | 25 |  |  | 237 |  |  | 165 |  |  | (234 | )
Net of tax | $ | (62 | ) |  | $ | (942 | ) |  | $ | (873 | ) |  | $ | 1,535 |
Amortization of pension and other postretirement benefit items (1):
Actuarial losses | $ | 1,640 |  |  | $ | 1,723 |  |  | $ | 5,120 |  |  | $ | 5,176 |
Prior-service costs | 24 |  |  | 20 |  |  | 71 |  |  | 79 |
Total before tax | 1,664 |  |  | 1,743 |  |  | 5,191 |  |  | 5,255 |
Tax benefit | (388 | ) |  | (619 | ) |  | (1,207 | ) |  | (1,868 | )
Net of tax | $ | 1,276 |  |  | $ | 1,124 |  |  | $ | 3,984 |  |  | $ | 3,387 |
Total reclassifications, net of tax | $ | 1,214 |  |  | $ | 182 |  |  | $ | 3,111 |  |  | $ | 4,922 |

(1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension
19

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
and other postretirement benefit plans (see Note 12 for additional information).
Note 11 — Taxes on income from continuing operations

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
Effective income tax rate | (2.3)% |  | 11.2% |  | 11.8% |  | 8.9%

The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The legislation significantly changed U.S. tax law by, among other things, permanently reducing corporate income tax rates from a maximum of 35% to 21%, effective January 1, 2018; implementing a territorial tax system, by generally providing for, among other things, a dividends received deduction on the foreign source portion of dividends received from a foreign corporation if specified conditions are met; and imposing a one-time repatriation tax on undistributed post-1986 foreign subsidiary earnings and profits, which are deemed repatriated for purposes of the tax. In addition, the TCJA imposes two new U.S. tax base erosion provisions: (1) the global intangible low-taxed income ("GILTI") provisions and (2) the base erosion and anti-abuse tax ("BEAT") provisions, which are explained in more detail in Note 13 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017.
In accordance with the applicable provisions of SEC Staff Accounting Bulletin No. 118, the Company included in its consolidated financial statements as of December 31, 2017 provisional amounts reflecting the tax impact related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities. During the third quarter of 2018, the Company recorded a $2.1 million tax benefit to adjust its initial provisional estimates for the TCJA in its provision for income taxes. The adjustment specifically related to the Company's initial estimate of the revaluation of certain deferred tax balances as a result of the reduced corporate income tax rate. To date, the Company has not made any other significant changes to its initial provisional estimates included in its consolidated financial statements as of December 31, 2017 and continues to evaluate the impact of the TCJA. Once the Company's accounting for the income tax effects of the TCJA is complete, the amounts with respect to the income tax effects of the TCJA may differ from the provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the TCJA.
The effective income tax rate for the three and nine months ended September 30, 2018 was (2.3)% and 11.8%, respectively, and was 11.2% and 8.9% for the three and nine months ended October 1, 2017, respectively. The effective income tax rate for the three and nine months ended September 30, 2018 as compared to the prior year periods reflects impacts of the TCJA, including the benefit of a lower U.S. corporate tax rate of 21.0% from the enactment of the TCJA, partially offset by a tax cost associated with GILTI. In addition, the effective tax rate for the three and nine months ended September 30, 2018 includes a tax benefit associated with the asset impairment charges described in Note 5, excess tax benefits associated with share based payments, and a non-deductible contingent consideration expense recognized in connection with an increase in the fair value of the NeoTract contingent consideration liability. The income tax rate for the nine months ended September 30, 2018 as compared to the prior year period reflects non-deductible termination benefits and other costs incurred in connection with the 2018 Footprint realignment plan. The effective tax rate for the nine months ended October 1, 2017 reflected a tax benefit associated with costs incurred in connection with the Vascular Solutions acquisition.
Note 12 — Pension and other postretirement benefits
The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. As of September 30, 2018, no further benefits are being accrued under the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement.
20

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
Net pension and other postretirement benefits expense (income) consist of the following:

| Pension Three Months Ended |  | Other Postretirement Benefits Three Months Ended |  | Pension Nine Months Ended |  | Other Postretirement Benefits Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in thousands)
Service cost | $ | 380 |  |  | $ | 725 |  |  | $ | (66 | ) |  | $ | 61 |  |  | $ | 1,135 |  |  | $ | 2,162 |  |  | $ | 38 |  |  | $ | 210 |
Interest cost | 3,681 |  |  | 3,773 |  |  | 285 |  |  | 426 |  |  | 11,119 |  |  | 11,347 |  |  | 1,042 |  |  | 1,183 |
Expected return on plan assets | (7,423 | ) |  | (6,607 | ) |  | — |  |  | — |  |  | (22,260 | ) |  | (20,100 | ) |  | — |  |  | — |
Net amortization and deferral | 1,687 |  |  | 1,668 |  |  | (23 | ) |  | 75 |  |  | 5,090 |  |  | 5,049 |  |  | 101 |  |  | 206 |
Net benefits expense (income) | $ | (1,675 | ) |  | $ | (441 | ) |  | $ | 196 |  |  | $ | 562 |  |  | $ | (4,916 | ) |  | $ | (1,542 | ) |  | $ | 1,181 |  |  | $ | 1,599 |

Note 13 — Commitments and contingent liabilities
Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed.
Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At September 30, 2018, the Company has recorded $1.0 million and $5.5 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of September 30, 2018. The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 15-20 years.
Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of September 30, 2018, the Company has recorded accrued liabilities of $1.8 million in connection with such contingencies, representing its best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters.
Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred.
Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various tax authorities. As of September 30, 2018, the most significant tax examinations in process are in Germany and Italy. The Company may establish reserves with respect to its uncertain tax positions, after which it adjusts the reserves to address developments with respect to its uncertain tax positions, including developments in these tax examinations. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results.
21

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
Other: The Company has various purchase commitments for materials, supplies and other items occurring in the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.
Note 14 — Segment information
Following the Company's acquisition of Vascular Solutions, the Company commenced an integration program under which it is combining the Vascular Solutions' business with some of its legacy businesses. As a result, effective during the fourth quarter 2017, the Company realigned its operating segments. The changes to the operating segments were also made to reflect the manner in which the Company’s chief operating decision maker assesses business performance and allocates resources. The Company now has the following seven reportable segments: Vascular North America, Interventional North America, Anesthesia North America, Surgical North America, Europe, Middle East and Africa ("EMEA"), Asia and Original Equipment and Development Services ("OEM"). In connection with the presentation of segment information, the Company will continue to present certain operating segments, which currently include the Interventional Urology North America, Respiratory North America and Latin America operating segments, in the “all other” category because separate information with regard to each of these operating segments is not material. All prior comparative periods presented have been restated to reflect these changes.
The following tables present the Company’s segment results for the three and nine months ended September 30, 2018 and October 1, 2017:

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in thousands)
Vascular North America | $ | 80,719 |  |  | $ | 75,065 |  |  | $ | 243,829 |  |  | $ | 232,872 |
Interventional North America | 66,726 |  |  | 60,719 |  |  | 191,878 |  |  | 159,002 |
Anesthesia North America | 53,160 |  |  | 50,819 |  |  | 154,215 |  |  | 148,107 |
Surgical North America | 42,545 |  |  | 40,804 |  |  | 123,930 |  |  | 131,464 |
EMEA | 139,541 |  |  | 137,034 |  |  | 452,826 |  |  | 409,077 |
Asia | 76,544 |  |  | 74,202 |  |  | 207,201 |  |  | 190,368 |
OEM | 54,838 |  |  | 48,589 |  |  | 153,286 |  |  | 137,067 |
All other | 95,599 |  |  | 47,471 |  |  | 279,603 |  |  | 143,240 |
Net revenues | $ | 609,672 |  |  | $ | 534,703 |  |  | $ | 1,806,768 |  |  | $ | 1,551,197 |

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in thousands)
Vascular North America | $ | 24,287 |  |  | $ | 17,803 |  |  | $ | 73,585 |  |  | $ | 54,565 |
Interventional North America | 17,142 |  |  | 12,485 |  |  | 47,772 |  |  | 13,265 |
Anesthesia North America | 16,811 |  |  | 15,084 |  |  | 48,860 |  |  | 48,444 |
Surgical North America | 15,906 |  |  | 13,618 |  |  | 47,709 |  |  | 47,285 |
EMEA | 21,916 |  |  | 24,198 |  |  | 80,221 |  |  | 69,102 |
Asia | 20,834 |  |  | 20,427 |  |  | 54,948 |  |  | 50,252 |
OEM | 15,049 |  |  | 12,256 |  |  | 37,617 |  |  | 31,714 |
All other | (5,587 | ) |  | 7,290 |  |  | (43,162 | ) |  | 25,634 |
Total segment operating profit (1) | 126,358 |  |  | 123,161 |  |  | 347,550 |  |  | 340,261 |
Unallocated expenses (2) | (44,253 | ) |  | (12,807 | ) |  | (145,112 | ) |  | (58,886 | )
Income from continuing operations before interest, loss on extinguishment of debt and taxes | $ | 82,105 |  |  | $ | 110,354 |  |  | $ | 202,438 |  |  | $ | 281,375 |

22

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)

(1) | Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved.

(2) | Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.

The following table provides total net revenues by geographic region (based on the Company's selling location) for the three and nine months ended September 30, 2018 and October 1, 2017:

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in thousands)
United States | $ | 365,271 |  |  | $ | 306,763 |  |  | $ | 1,066,095 |  |  | $ | 903,201 |
Europe | 160,498 |  |  | 148,808 |  |  | 500,697 |  |  | 434,223 |
Asia | 60,414 |  |  | 59,169 |  |  | 170,458 |  |  | 156,074 |
All other | 23,489 |  |  | 19,963 |  |  | 69,518 |  |  | 57,699 |
Net revenues | $ | 609,672 |  |  | $ | 534,703 |  |  | $ | 1,806,768 |  |  | $ | 1,551,197 |

23

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
Note 15 — Condensed consolidating guarantor financial information
The Company’s $250 million principal amount of 5.25% Senior Notes due 2024 (the “2024 Notes”), $400 million principal amount of 4.875% Senior Notes due 2026 (the “2026 Notes”) and $500 million principal amount of 4.625% Senior Notes due 2027 (the “2027 Notes," and collectively with the 2024 Notes and the 2026 Notes, the "Senior Notes") are issued by Teleflex Incorporated (the “Parent Company”), and payment of the Parent Company's obligations under the Senior Notes are guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The 2024 Notes, 2026 Notes and 2027 Notes are guaranteed by the same Guarantor Subsidiaries. The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income for the three and nine months ended September 30, 2018 and October 1, 2017, condensed consolidating balance sheets as of September 30, 2018 and December 31, 2017 and condensed consolidating statements of cash flows for the nine months ended September 30, 2018 and October 1, 2017, provide consolidated information for:

a. | Parent Company, the issuer of the guaranteed obligations;

b. | Guarantor Subsidiaries, on a combined basis;

c. | Non-Guarantor Subsidiaries (i.e., those subsidiaries of the Parent Company that have not guaranteed payment of the Senior Notes), on a combined basis; and

d. | Parent Company and its subsidiaries on a consolidated basis.

The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidating financial information, except for the use of the equity method of accounting to reflect ownership interests in subsidiaries, which are eliminated upon consolidation.
Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries.
During the first quarter 2018, a Guarantor Subsidiary merged with and into Parent; the transaction was reflected as of the beginning of the earliest period presented in the condensed consolidating financial statements.
24

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

| Three Months Ended September 30, 2018
| Parent Company |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Condensed Consolidated
| (Dollars in thousands)
Net revenues | $ | — |  |  | $ | 398,961 |  |  | $ | 322,010 |  |  | $ | (111,299 | ) |  | $ | 609,672 |
Cost of goods sold | — |  |  | 232,209 |  |  | 146,301 |  |  | (111,411 | ) |  | 267,099 |
Gross profit | — |  |  | 166,752 |  |  | 175,709 |  |  | 112 |  |  | 342,573 |
Selling, general and administrative expenses | 11,347 |  |  | 130,773 |  |  | 72,796 |  |  | (22 | ) |  | 214,894 |
Research and development expenses | 378 |  |  | 19,482 |  |  | 6,505 |  |  | — |  |  | 26,365 |
Restructuring charges | — |  |  | 17,128 |  |  | 2,081 |  |  | — |  |  | 19,209 |
(Loss) income from continuing operations before interest and taxes | (11,725 | ) |  | (631 | ) |  | 94,327 |  |  | 134 |  |  | 82,105 |
Interest, net | 25,191 |  |  | 1,057 |  |  | 603 |  |  | — |  |  | 26,851 |
(Loss) income from continuing operations before taxes | (36,916 | ) |  | (1,688 | ) |  | 93,724 |  |  | 134 |  |  | 55,254 |
(Benefit) taxes on (loss) income from continuing operations | (13,449 | ) |  | (2,562 | ) |  | 14,712 |  |  | 13 |  |  | (1,286 | )
Equity in net income of consolidated subsidiaries | 80,007 |  |  | 68,943 |  |  | 372 |  |  | (149,322 | ) |  | — |
Income from continuing operations | 56,540 |  |  | 69,817 |  |  | 79,384 |  |  | (149,201 | ) |  | 56,540 |
Operating loss from discontinued operations | (83 | ) |  | — |  |  | — |  |  | — |  |  | (83 | )
Tax benefit on loss from discontinued operations | (67 | ) |  | — |  |  | — |  |  | — |  |  | (67 | )
Loss from discontinued operations | (16 | ) |  | — |  |  | — |  |  | — |  |  | (16 | )
Net income | 56,524 |  |  | 69,817 |  |  | 79,384 |  |  | (149,201 | ) |  | 56,524 |
Other comprehensive income | 17,253 |  |  | 14,107 |  |  | 16,947 |  |  | (31,054 | ) |  | 17,253 |
Comprehensive income | $ | 73,777 |  |  | $ | 83,924 |  |  | $ | 96,331 |  |  | $ | (180,255 | ) |  | $ | 73,777 |

25

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)

| Three Months Ended October 1, 2017
| Parent Company |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Condensed Consolidated
| (Dollars in thousands)
Net revenues | $ | — |  |  | $ | 335,051 |  |  | $ | 303,676 |  |  | $ | (104,024 | ) |  | $ | 534,703 |
Cost of goods sold | — |  |  | 194,262 |  |  | 149,302 |  |  | (104,088 | ) |  | 239,476 |
Gross profit | — |  |  | 140,789 |  |  | 154,374 |  |  | 64 |  |  | 295,227 |
Selling, general and administrative expenses | 10,536 |  |  | 89,315 |  |  | 64,046 |  |  | (126 | ) |  | 163,771 |
Research and development expenses | 220 |  |  | 14,788 |  |  | 6,186 |  |  | — |  |  | 21,194 |
Restructuring charges | — |  |  | 552 |  |  | (644 | ) |  | — |  |  | (92 | )
(Loss) income from continuing operations before interest, extinguishment of debt and taxes | (10,756 | ) |  | 36,134 |  |  | 84,786 |  |  | 190 |  |  | 110,354 |
Interest, net | 29,231 |  |  | (9,102 | ) |  | 849 |  |  | — |  |  | 20,978 |
(Loss) income from continuing operations before taxes | (39,987 | ) |  | 45,236 |  |  | 83,937 |  |  | 190 |  |  | 89,376 |
(Benefit) taxes on (loss) income from continuing operations | (21,968 | ) |  | 14,576 |  |  | 17,364 |  |  | 6 |  |  | 9,978 |
Equity in net income of consolidated subsidiaries | 97,417 |  |  | 61,027 |  |  | 257 |  |  | (158,701 | ) |  | — |
Income from continuing operations | 79,398 |  |  | 91,687 |  |  | 66,830 |  |  | (158,517 | ) |  | 79,398 |
Operating loss from discontinued operations | (3,749 | ) |  | — |  |  | — |  |  | — |  |  | (3,749 | )
Tax benefit on loss from discontinued operations | (1,366 | ) |  | — |  |  | — |  |  | — |  |  | (1,366 | )
Loss from discontinued operations | (2,383 | ) |  | — |  |  | — |  |  | — |  |  | (2,383 | )
Net income | 77,015 |  |  | 91,687 |  |  | 66,830 |  |  | (158,517 | ) |  | 77,015 |
Other comprehensive income | 43,845 |  |  | 30,196 |  |  | 56,286 |  |  | (86,482 | ) |  | 43,845 |
Comprehensive income | $ | 120,860 |  |  | $ | 121,883 |  |  | $ | 123,116 |  |  | $ | (244,999 | ) |  | $ | 120,860 |

26

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)

| Nine Months Ended September 30, 2018
| Parent Company |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Condensed Consolidated
| (Dollars in thousands)
Net revenues | $ | — |  |  | $ | 1,169,684 |  |  | $ | 968,298 |  |  | $ | (331,214 | ) |  | $ | 1,806,768 |
Cost of goods sold | — |  |  | 681,300 |  |  | 431,841 |  |  | (324,994 | ) |  | 788,147 |
Gross profit | — |  |  | 488,384 |  |  | 536,457 |  |  | (6,220 | ) |  | 1,018,621 |
Selling, general and administrative expenses | 32,958 |  |  | 401,252 |  |  | 226,290 |  |  | (352 | ) |  | 660,148 |
Research and development expenses | 1,094 |  |  | 57,668 |  |  | 19,648 |  |  | — |  |  | 78,410 |
Restructuring and impairment charges | — |  |  | 20,581 |  |  | 57,044 |  |  | — |  |  | 77,625 |
(Loss) income from continuing operations before interest and taxes | (34,052 | ) |  | 8,883 |  |  | 233,475 |  |  | (5,868 | ) |  | 202,438 |
Interest, net | 72,120 |  |  | 5,066 |  |  | 1,801 |  |  | — |  |  | 78,987 |
(Loss) income from continuing operations before taxes | (106,172 | ) |  | 3,817 |  |  | 231,674 |  |  | (5,868 | ) |  | 123,451 |
(Benefit) taxes on (loss) income from continuing operations | (39,859 | ) |  | 11,347 |  |  | 44,134 |  |  | (1,090 | ) |  | 14,532 |
Equity in net income of consolidated subsidiaries | 176,511 |  |  | 170,276 |  |  | 1,007 |  |  | (347,794 | ) |  | — |
Income from continuing operations | 110,198 |  |  | 162,746 |  |  | 188,547 |  |  | (352,572 | ) |  | 108,919 |
Operating (loss) income from discontinued operations | (33 | ) |  | — |  |  | 1,279 |  |  | — |  |  | 1,246 |
Tax benefit on loss from discontinued operations | (47 | ) |  | — |  |  | — |  |  | — |  |  | (47 | )
Income from discontinued operations | 14 |  |  | — |  |  | 1,279 |  |  | — |  |  | 1,293 |
Net income | 110,212 |  |  | 162,746 |  |  | 189,826 |  |  | (352,572 | ) |  | 110,212 |
Other comprehensive loss | (24,076 | ) |  | (30,691 | ) |  | (26,551 | ) |  | 57,242 |  |  | (24,076 | )
Comprehensive income | $ | 86,136 |  |  | $ | 132,055 |  |  | $ | 163,275 |  |  | $ | (295,330 | ) |  | $ | 86,136 |

27

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)

| Nine Months Ended October 1, 2017
| Parent Company |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Condensed Consolidated
| (Dollars in thousands)
Net revenues | $ | — |  |  | $ | 989,314 |  |  | $ | 876,968 |  |  | $ | (315,085 | ) |  | $ | 1,551,197 |
Cost of goods sold | — |  |  | 576,465 |  |  | 445,638 |  |  | (311,977 | ) |  | 710,126 |
Gross profit | — |  |  | 412,849 |  |  | 431,330 |  |  | (3,108 | ) |  | 841,071 |
Selling, general and administrative expenses | 38,523 |  |  | 278,529 |  |  | 169,224 |  |  | 398 |  |  | 486,674 |
Research and development expenses | 719 |  |  | 39,568 |  |  | 19,012 |  |  | — |  |  | 59,299 |
Restructuring charges | — |  |  | 7,261 |  |  | 6,462 |  |  | — |  |  | 13,723 |
(Loss) income from continuing operations before interest, extinguishment of debt and taxes | (39,242 | ) |  | 87,491 |  |  | 236,632 |  |  | (3,506 | ) |  | 281,375 |
Interest, net | 80,737 |  |  | (25,245 | ) |  | 2,776 |  |  | — |  |  | 58,268 |
Loss on extinguishment of debt | 5,593 |  |  | — |  |  | — |  |  | — |  |  | 5,593 |
(Loss) income from continuing operations before taxes | (125,572 | ) |  | 112,736 |  |  | 233,856 |  |  | (3,506 | ) |  | 217,514 |
(Benefit) taxes on (loss) income from continuing operations | (57,679 | ) |  | 33,873 |  |  | 43,803 |  |  | (593 | ) |  | 19,404 |
Equity in net income of consolidated subsidiaries | 266,003 |  |  | 175,690 |  |  | 713 |  |  | (442,406 | ) |  | — |
Income from continuing operations | 198,110 |  |  | 254,553 |  |  | 190,766 |  |  | (445,319 | ) |  | 198,110 |
Operating loss from discontinued operations | (4,597 | ) |  | — |  |  | — |  |  | — |  |  | (4,597 | )
Tax benefit on loss from discontinued operations | (1,675 | ) |  | — |  |  | — |  |  | — |  |  | (1,675 | )
Loss from discontinued operations | (2,922 | ) |  | — |  |  | — |  |  | — |  |  | (2,922 | )
Net income | 195,188 |  |  | 254,553 |  |  | 190,766 |  |  | (445,319 | ) |  | 195,188 |
Other comprehensive income | 163,267 |  |  | 147,727 |  |  | 179,561 |  |  | (327,288 | ) |  | 163,267 |
Comprehensive income | $ | 358,455 |  |  | $ | 402,280 |  |  | $ | 370,327 |  |  | $ | (772,607 | ) |  | $ | 358,455 |

28

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATING BALANCE SHEETS

| September 30, 2018
| Parent Company |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Condensed Consolidated
| (Dollars in thousands)
ASSETS |  |  |  |  |  |  |  |  |
Current assets |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | 47,766 |  |  | $ | 1,288 |  |  | $ | 307,222 |  |  | $ | — |  |  | $ | 356,276 |
Accounts receivable, net | 2,932 |  |  | 55,452 |  |  | 310,942 |  |  | 5,015 |  |  | 374,341 |
Accounts receivable from consolidated subsidiaries | 24,606 |  |  | 994,236 |  |  | 351,740 |  |  | (1,370,582 | ) |  | — |
Inventories, net | — |  |  | 245,600 |  |  | 197,784 |  |  | (32,318 | ) |  | 411,066 |
Prepaid expenses and other current assets | 14,379 |  |  | 12,409 |  |  | 24,403 |  |  | 3,982 |  |  | 55,173 |
Prepaid taxes | 33,766 |  |  | — |  |  | 6,949 |  |  | — |  |  | 40,715 |
Assets held for sale | — |  |  | 3,239 |  |  | — |  |  | — |  |  | 3,239 |
Total current assets | 123,449 |  |  | 1,312,224 |  |  | 1,199,040 |  |  | (1,393,903 | ) |  | 1,240,810 |
Property, plant and equipment, net | 3,177 |  |  | 238,079 |  |  | 180,009 |  |  | — |  |  | 421,265 |
Goodwill | — |  |  | 1,245,455 |  |  | 977,974 |  |  | — |  |  | 2,223,429 |
Intangibles assets, net | 95 |  |  | 1,274,994 |  |  | 987,729 |  |  | — |  |  | 2,262,818 |
Investments in consolidated subsidiaries | 5,929,366 |  |  | 1,673,596 |  |  | 20,625 |  |  | (7,623,587 | ) |  | — |
Deferred tax assets | — |  |  | — |  |  | 4,589 |  |  | (2,284 | ) |  | 2,305 |
Notes receivable and other amounts due from consolidated subsidiaries | 2,265,457 |  |  | 2,445,390 |  |  | — |  |  | (4,710,847 | ) |  | — |
Other assets | 30,226 |  |  | 6,057 |  |  | 13,810 |  |  | — |  |  | 50,093 |
Total assets | $ | 8,351,770 |  |  | $ | 8,195,795 |  |  | $ | 3,383,776 |  |  | $ | (13,730,621 | ) |  | $ | 6,200,720 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |
Current liabilities |  |  |  |  |  |  |  |  |
Current borrowings | $ | 27,250 |  |  | $ | — |  |  | $ | 50,000 |  |  | $ | — |  |  | $ | 77,250 |
Accounts payable | 4,254 |  |  | 54,791 |  |  | 38,583 |  |  | — |  |  | 97,628 |
Accounts payable to consolidated subsidiaries | 1,024,109 |  |  | 280,381 |  |  | 66,092 |  |  | (1,370,582 | ) |  | — |
Accrued expenses | 17,966 |  |  | 36,206 |  |  | 51,412 |  |  | — |  |  | 105,584 |
Current portion of contingent consideration | — |  |  | 101,573 |  |  | 1,091 |  |  | — |  |  | 102,664 |
Payroll and benefit-related liabilities | 18,184 |  |  | 31,405 |  |  | 44,543 |  |  | — |  |  | 94,132 |
Accrued interest | 20,595 |  |  | — |  |  | 28 |  |  | — |  |  | 20,623 |
Income taxes payable | — |  |  | — |  |  | 14,437 |  |  | (1,090 | ) |  | 13,347 |
Other current liabilities | 1,637 |  |  | 33,589 |  |  | 2,839 |  |  | — |  |  | 38,065 |
Total current liabilities | 1,113,995 |  |  | 537,945 |  |  | 269,025 |  |  | (1,371,672 | ) |  | 549,293 |
Long-term borrowings | 2,075,834 |  |  | — |  |  | — |  |  | — |  |  | 2,075,834 |
Deferred tax liabilities | 92,270 |  |  | 264,288 |  |  | 251,808 |  |  | (2,284 | ) |  | 606,082 |
Pension and postretirement benefit liabilities | 49,853 |  |  | 32,019 |  |  | 17,478 |  |  | — |  |  | 99,350 |
Noncurrent liability for uncertain tax positions | 1,986 |  |  | 8,352 |  |  | 2,832 |  |  | — |  |  | 13,170 |
Notes payable and other amounts due to consolidated subsidiaries | 2,370,469 |  |  | 2,135,450 |  |  | 204,928 |  |  | (4,710,847 | ) |  | — |
Noncurrent contingent consideration | — |  |  | 131,578 |  |  | 10,332 |  |  | — |  |  | 141,910 |
Other liabilities | 140,298 |  |  | 9,026 |  |  | 58,692 |  |  | — |  |  | 208,016 |
Total liabilities | 5,844,705 |  |  | 3,118,658 |  |  | 815,095 |  |  | (6,084,803 | ) |  | 3,693,655 |
Total shareholders' equity | 2,507,065 |  |  | 5,077,137 |  |  | 2,568,681 |  |  | (7,645,818 | ) |  | 2,507,065 |
Total liabilities and shareholders' equity | $ | 8,351,770 |  |  | $ | 8,195,795 |  |  | $ | 3,383,776 |  |  | $ | (13,730,621 | ) |  | $ | 6,200,720 |

29

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)

| December 31, 2017
| Parent Company |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Condensed Consolidated
| (Dollars in thousands)
ASSETS |  |  |  |  |  |  |  |  |
Current assets |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | 37,803 |  |  | $ | 8,933 |  |  | $ | 286,822 |  |  | $ | — |  |  | $ | 333,558 |
Accounts receivable, net | 2,414 |  |  | 57,818 |  |  | 280,980 |  |  | 4,663 |  |  | 345,875 |
Accounts receivable from consolidated subsidiaries | 14,478 |  |  | 1,177,246 |  |  | 343,115 |  |  | (1,534,839 | ) |  | — |
Inventories, net | — |  |  | 245,533 |  |  | 176,490 |  |  | (26,279 | ) |  | 395,744 |
Prepaid expenses and other current assets | 14,874 |  |  | 9,236 |  |  | 19,790 |  |  | 3,982 |  |  | 47,882 |
Prepaid taxes | — |  |  | — |  |  | 5,748 |  |  | — |  |  | 5,748 |
Total current assets | 69,569 |  |  | 1,498,766 |  |  | 1,112,945 |  |  | (1,552,473 | ) |  | 1,128,807 |
Property, plant and equipment, net | 2,088 |  |  | 213,663 |  |  | 167,248 |  |  | — |  |  | 382,999 |
Goodwill | — |  |  | 1,246,144 |  |  | 989,448 |  |  | — |  |  | 2,235,592 |
Intangibles assets, net | — |  |  | 1,355,275 |  |  | 1,028,473 |  |  | — |  |  | 2,383,748 |
Investments in consolidated subsidiaries | 5,806,244 |  |  | 1,674,077 |  |  | 19,620 |  |  | (7,499,941 | ) |  | — |
Deferred tax assets | — |  |  | — |  |  | 6,071 |  |  | (2,261 | ) |  | 3,810 |
Notes receivable and other amounts due from consolidated subsidiaries | 2,452,101 |  |  | 2,231,832 |  |  | — |  |  | (4,683,933 | ) |  | — |
Other assets | 31,173 |  |  | 6,397 |  |  | 8,966 |  |  | — |  |  | 46,536 |
Total assets | $ | 8,361,175 |  |  | $ | 8,226,154 |  |  | $ | 3,332,771 |  |  | $ | (13,738,608 | ) |  | $ | 6,181,492 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |
Current liabilities |  |  |  |  |  |  |  |  |
Current borrowings | $ | 36,625 |  |  | $ | — |  |  | $ | 50,000 |  |  | $ | — |  |  | $ | 86,625 |
Accounts payable | 4,269 |  |  | 46,992 |  |  | 40,766 |  |  | — |  |  | 92,027 |
Accounts payable to consolidated subsidiaries | 1,211,568 |  |  | 261,121 |  |  | 62,150 |  |  | (1,534,839 | ) |  | — |
Accrued expenses | 17,957 |  |  | 31,827 |  |  | 47,069 |  |  | — |  |  | 96,853 |
Current portion of contingent consideration | — |  |  | 74,224 |  |  | — |  |  | — |  |  | 74,224 |
Payroll and benefit-related liabilities | 21,145 |  |  | 44,009 |  |  | 42,261 |  |  | — |  |  | 107,415 |
Accrued interest | 6,133 |  |  | — |  |  | 32 |  |  | — |  |  | 6,165 |
Income taxes payable | 4,352 |  |  | — |  |  | 7,162 |  |  | — |  |  | 11,514 |
Other current liabilities | 1,461 |  |  | 3,775 |  |  | 3,817 |  |  | — |  |  | 9,053 |
Total current liabilities | 1,303,510 |  |  | 461,948 |  |  | 253,257 |  |  | (1,534,839 | ) |  | 483,876 |
Long-term borrowings | 2,162,927 |  |  | — |  |  | — |  |  | — |  |  | 2,162,927 |
Deferred tax liabilities | 88,512 |  |  | 265,426 |  |  | 251,999 |  |  | (2,261 | ) |  | 603,676 |
Pension and postretirement benefit liabilities | 70,860 |  |  | 32,750 |  |  | 17,800 |  |  | — |  |  | 121,410 |
Noncurrent liability for uncertain tax positions | 1,117 |  |  | 8,196 |  |  | 2,983 |  |  | — |  |  | 12,296 |
Notes payable and other amounts due to consolidated subsidiaries | 2,155,146 |  |  | 2,320,611 |  |  | 208,176 |  |  | (4,683,933 | ) |  | — |
Noncurrent contingent consideration | — |  |  | 186,923 |  |  | 10,989 |  |  | — |  |  | 197,912 |
Other liabilities | 148,572 |  |  | 7,850 |  |  | 12,442 |  |  | — |  |  | 168,864 |
Total liabilities | 5,930,644 |  |  | 3,283,704 |  |  | 757,646 |  |  | (6,221,033 | ) |  | 3,750,961 |
Total shareholders' equity | 2,430,531 |  |  | 4,942,450 |  |  | 2,575,125 |  |  | (7,517,575 | ) |  | 2,430,531 |
Total liabilities and shareholders' equity | $ | 8,361,175 |  |  | $ | 8,226,154 |  |  | $ | 3,332,771 |  |  | $ | (13,738,608 | ) |  | $ | 6,181,492 |

30

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS

| Nine Months Ended September 30, 2018
| Parent Company |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Condensed Consolidated
| (Dollars in thousands)
Net cash (used in) provided by operating activities from continuing operations | $ | (202,209 | ) |  | $ | 382,389 |  |  | $ | 268,390 |  |  | $ | (145,626 | ) |  | $ | 302,944 |
Cash flows from investing activities of continuing operations: |  |  |  |  |  |  |  |  |
Expenditures for property, plant and equipment | (1,524 | ) |  | (23,686 | ) |  | (30,541 | ) |  | — |  |  | (55,751 | )
Proceeds from sale of investments | 28,239 |  |  | — |  |  | — |  |  | (28,239 | ) |  | — |
Payments for businesses and intangibles acquired, net of cash acquired | (100 | ) |  | 1,404 |  |  | (23,854 | ) |  | — |  |  | (22,550 | )
Net cash provided by (used in) investing activities from continuing operations | 26,615 |  |  | (22,282 | ) |  | (54,395 | ) |  | (28,239 | ) |  | (78,301 | )
Cash flows from financing activities of continuing operations: |  |  |  |  |  |  |  |  |
Reduction in borrowings | (98,500 | ) |  | — |  |  | — |  |  | — |  |  | (98,500 | )
Debt extinguishment, issuance and amendment fees | (188 | ) |  | — |  |  | — |  |  | — |  |  | (188 | )
Net proceeds from share based compensation plans and the related tax impacts | 18,666 |  |  | — |  |  | — |  |  | — |  |  | 18,666 |
Payments for contingent consideration | — |  |  | (73,152 | ) |  | — |  |  | — |  |  | (73,152 | )
Dividends paid | (46,526 | ) |  | — |  |  | — |  |  | — |  |  | (46,526 | )
Intercompany transactions | 312,806 |  |  | (294,600 | ) |  | (46,445 | ) |  | 28,239 |  |  | — |
Intercompany dividends paid | — |  |  | — |  |  | (145,626 | ) |  | 145,626 |  |  | — |
Net cash provided by (used in) financing activities from continuing operations | 186,258 |  |  | (367,752 | ) |  | (192,071 | ) |  | 173,865 |  |  | (199,700 | )
Cash flows from discontinued operations: |  |  |  |  |  |  |  |  |
Net cash used in operating activities | (701 | ) |  | — |  |  | — |  |  | — |  |  | (701 | )
Net cash used in discontinued operations | (701 | ) |  | — |  |  | — |  |  | — |  |  | (701 | )
Effect of exchange rate changes on cash and cash equivalents | — |  |  | — |  |  | (1,524 | ) |  | — |  |  | (1,524 | )
Net increase (decrease) in cash and cash equivalents | 9,963 |  |  | (7,645 | ) |  | 20,400 |  |  | — |  |  | 22,718 |
Cash and cash equivalents at the beginning of the period | 37,803 |  |  | 8,933 |  |  | 286,822 |  |  | — |  |  | 333,558 |
Cash and cash equivalents at the end of the period | $ | 47,766 |  |  | $ | 1,288 |  |  | $ | 307,222 |  |  | $ | — |  |  | $ | 356,276 |

31

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)

| Nine Months Ended October 1, 2017
| Parent Company |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Condensed Consolidated
| (Dollars in thousands)
Net cash (used in) provided by operating activities from continuing operations | $ | (156,643 | ) |  | $ | 300,961 |  |  | $ | 237,308 |  |  | $ | (61,918 | ) |  | $ | 319,708 |
Cash flows from investing activities of continuing operations: |  |  |  |  |  |  |  |  |
Expenditures for property, plant and equipment | (233 | ) |  | (27,527 | ) |  | (26,217 | ) |  | — |  |  | (53,977 | )
Proceeds from sale of assets | 464,982 |  |  | — |  |  | 6,332 |  |  | (464,982 | ) |  | 6,332 |
Payments for businesses and intangibles acquired, net of cash acquired | (975,524 | ) |  | — |  |  | (35,187 | ) |  | — |  |  | (1,010,711 | )
Net cash used in investing activities from continuing operations | (510,775 | ) |  | (27,527 | ) |  | (55,072 | ) |  | (464,982 | ) |  | (1,058,356 | )
Cash flows from financing activities of continuing operations: |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from new borrowings | 1,963,500 |  |  | — |  |  | — |  |  | — |  |  | 1,963,500 |
Reduction in borrowings | (747,576 | ) |  | — |  |  | — |  |  | — |  |  | (747,576 | )
Debt extinguishment, issuance and amendment fees | (19,114 | ) |  | — |  |  | — |  |  | — |  |  | (19,114 | )
Net proceeds from share based compensation plans and the related tax impacts | 4,739 |  |  | — |  |  | — |  |  | — |  |  | 4,739 |
Payments for contingent consideration | — |  |  | (245 | ) |  | — |  |  | — |  |  | (245 | )
Dividends paid | (45,905 | ) |  | — |  |  | — |  |  | — |  |  | (45,905 | )
Intercompany transactions | (456,468 | ) |  | 474,192 |  |  | (482,706 | ) |  | 464,982 |  |  | — |
Intercompany dividends paid | — |  |  | — |  |  | (61,918 | ) |  | 61,918 |  |  | — |
Net cash provided by (used in) financing activities from continuing operations | 699,176 |  |  | 473,947 |  |  | (544,624 | ) |  | 526,900 |  |  | 1,155,399 |
Cash flows from discontinued operations: |  |  |  |  |  |  |  |  |  |  |  |  |
Net cash used in operating activities | (1,140 | ) |  | — |  |  | — |  |  | — |  |  | (1,140 | )
Net cash used in discontinued operations | (1,140 | ) |  | — |  |  | — |  |  | — |  |  | (1,140 | )
Effect of exchange rate changes on cash and cash equivalents | — |  |  | — |  |  | 58,173 |  |  | — |  |  | 58,173 |
Net increase (decrease) in cash and cash equivalents | 30,618 |  |  | 747,381 |  |  | (304,215 | ) |  | — |  |  | 473,784 |
Cash and cash equivalents at the beginning of the period | 14,571 |  |  | 1,031 |  |  | 528,187 |  |  | — |  |  | 543,789 |
Cash and cash equivalents at the end of the period | $ | 45,189 |  |  | $ | 748,412 |  |  | $ | 223,972 |  |  | $ | — |  |  | $ | 1,017,573 |

32

TELEFLEX INCORPORATED
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)
(Unaudited)
Note 16 — Subsequent events
Cross-currency interest rate swap
On October 4, 2018, the Company entered into cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, the Company has notionally exchanged $500 million at an annual interest rate of 4.625% for €433.9 million at an annual interest rate of 1.942%. The swap agreements are designated as net investment hedges and expire on October 4, 2023.
Essential Medical, Inc. acquisition
On October 4, 2018, the Company acquired Essential Medical, Inc. ("Essential Medical"), a medical device company that developed the CE marked MANTA Vascular Closure Device, which is designed for closure of large bore arteriotomies and complements the Company's interventional product portfolio. Under the terms of the acquisition agreement, the Company acquired Essential Medical for an initial purchase price of $60 million in cash, subject to customary purchase price adjustments. The agreement also provides for additional payments of up to $100 million if certain sales and regulatory goals are met.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
All statements made in this Quarterly Report on Form 10-Q, other than statements of historical fact, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “guidance,” “potential,” “continue,” “project,” “forecast,” “confident,” “prospects” and similar expressions typically are used to identify forward-looking statements. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about our business and the industry and markets in which we operate. These statements are not guarantees of future performance and are subject to risks and uncertainties, which are difficult to predict. Therefore, actual outcomes and results may differ materially from those expressed or implied by these forward-looking statements due to a number of factors, including changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, sovereign debt issues and the impact of the United Kingdom’s vote to leave the European Union; difficulties entering new markets; and general economic conditions. For a further discussion of the risks relating to our business, see Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2017. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.
Overview
Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure. We are focused on achieving consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies.
We evaluate our portfolio of products and businesses on an ongoing basis to ensure alignment with our overall objectives. Based on our evaluation, we may identify opportunities to divest businesses and product lines that do not
33

meet our objectives. In addition, we seek to optimize utilization of our facilities through restructuring initiatives designed to further improve our cost structure and enhance our competitive position. We also may continue to explore opportunities to expand the size of our business and improve operating margins through a combination of acquisitions and distributor to direct sales conversions, which generally involve our elimination of a distributor from the sales channel, either by acquiring the distributor or terminating the distributor relationship (in some instances, the conversions involve our acquisition or termination of a master distributor and the continued sale of our products through sub-distributors or through new distributors). Distributor to direct sales conversions are designed to facilitate improved product pricing and more direct access to the end users of our products within the sales channel.
On October 4, 2018, we acquired Essential Medical, Inc. ("Essential Medical"), a medical device company that developed the CE marked MANTA Vascular Closure Device, which is designed for closure of large bore arteriotomies and complements our interventional product portfolio. Under the terms of the acquisition agreement, we acquired Essential Medical for an initial purchase price of $60 million in cash subject to customary purchase price adjustments. The agreement also provides for additional payments of up to $100 million if certain sales and regulatory goals are met.
On June 21, 2018, we acquired certain assets of QT Vascular LTD ("QT Vascular"), a medical device company that developed and marketed coronary balloon catheters, which complement our interventional product portfolio. The consideration transferred for the assets was $20.6 million.
On May 1, 2018, we initiated a restructuring plan involving the relocation of certain manufacturing operations to an existing lower-cost location, the outsourcing of certain distribution operations and related workforce reductions (the "2018 Footprint realignment plan"). See "Result of Operations - Restructuring charges" below and Note 5 to the condensed consolidated financial statements included in this report for additional information.
On October 2, 2017, we acquired NeoTract, Inc. ("NeoTract"), a medical device company that developed and commercialized the UroLift System, a minimally invasive medical device for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. We made initial payments of $725.6 million in cash less a favorable working capital adjustment of $1.4 million. Additionally, the estimated fair value of contingent consideration related to NeoTract sales-based milestones as of September 30, 2018 was $229.4 million. The contingent consideration liability represents the estimated fair value of our obligations to make additional payments of up to $300 million in the aggregate if specified net sales goals through the end of 2020 are achieved.
On February 17, 2017, we acquired Vascular Solutions, Inc. (“Vascular Solutions”), a medical device company that developed and marketed clinical products for use in minimally invasive coronary and peripheral vascular procedures, for an aggregate purchase price of $975.5 million.
During 2017 we also completed acquisitions related to our anesthesia and respiratory product portfolios and distributor to direct sales conversions. The total fair value of the consideration related to these acquisitions was $80.1 million.
See Note 4 to the condensed consolidated financial statements included in this report for additional information.
Change in Reportable Segments
Following our acquisition of Vascular Solutions, we commenced an integration program under which we are combining Vascular Solutions' businesses with some of our legacy businesses. As a result, effective during the fourth quarter of 2017, we realigned our operating segments. The changes to the operating segments were also made to reflect the manner in which our chief operating decision maker assesses business performance and allocates resources. We now have the following seven reportable segments: Vascular North America, Interventional North America, Anesthesia North America, Surgical North America, Europe, Middle East and Africa ("EMEA"), Asia and Original Equipment and Development Services ("OEM"). In connection with the presentation of segment information, we will continue to present certain segments, which currently include our Interventional Urology North America, Respiratory North America and Latin America operating segments, in the “all other” category because separate information with respect to each of these operating segments is not material. All prior comparative periods presented have been restated to reflect these changes.
34

Results of Operations
As used in this discussion, "new products" are products for which commercial sales have commenced within the past 36 months, and “existing products” are products for which commercial sales commenced more than 36 months ago. Discussion of results of operations items that reference the effect of one or more acquired businesses (except as noted below with respect to acquired distributors) generally reflects the impact of the acquisitions within the first 12 months following the date of the acquisition. In addition to increases and decreases in the per unit selling prices of our products to our customers, our discussion of the impact of product price increases and decreases also reflects the impact on the pricing of our products resulting from the elimination of the distributor, either through acquisition or termination of the distributor, from the sales channel.
Certain financial information is presented on a rounded basis, which may cause minor differences.
Net Revenues

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in millions)
Net Revenues | $ | 609.7 |  |  | $ | 534.7 |  |  | $ | 1,806.8 |  |  | $ | 1,551.2 |

Net revenues for the three months ended September 30, 2018 increased $75.0 million, or 14.0%, compared to the prior year period. The increase is primarily attributable to net revenues of $49.9 million generated by acquired businesses, primarily NeoTract, and a $17.5 million increase in sales volumes of existing products.
Net revenues for the nine months ended September 30, 2018 increased $255.6 million, or 16.5%, compared to the prior year period. The increase is primarily attributable to net revenues of $163.2 million generated by acquired businesses, favorable fluctuations in foreign currency exchange rates of $33.8 million and, to a lesser extent, increases in new product sales and sales volumes of existing products.
Gross profit

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in millions)
Gross profit | $ | 342.6 |  |  | $ | 295.2 |  |  | $ | 1,018.6 |  |  | $ | 841.1 |
Percentage of sales | 56.2 | % |  | 55.2 | % |  | 56.4 | % |  | 54.2 | %

Gross margin for the three months ended September 30, 2018 increased 100 basis points, or 1.8%, compared to the prior year period. The increase in gross margin reflects the favorable impact of gross profit generated by NeoTract, the impact of favorable fluctuations in foreign currency exchange rates and the impact of price increases. The increases in gross margin were partially offset by unfavorable mix and higher manufacturing costs.
Gross margin for the nine months ended September 30, 2018 increased 220 basis points, or 4.1%, compared to the prior year period. The increase in gross margin reflects the favorable impact of gross profit generated by acquired businesses, mainly NeoTract and Vascular Solutions, and the impact of favorable fluctuations in foreign currency exchange rates partially offset by unfavorable mix. The increase in gross margin also reflects the adverse impact on gross margin for the nine months ended October 1, 2017 of the step-up in the carrying value of inventory recognized in connection with the Vascular Solutions acquisition.
35

Selling, general and administrative

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in millions)
Selling, general and administrative | $ | 214.9 |  |  | $ | 163.8 |  |  | $ | 660.1 |  |  | $ | 486.7 |
Percentage of sales | 35.2 | % |  | 30.6 | % |  | 36.5 | % |  | 31.4 | %

Selling, general and administrative expenses for the three months ended September 30, 2018 increased $51.1 million compared to the prior year period. The increase is primarily attributable to expenses incurred by our acquired businesses (primarily Neotract, which we acquired in October 2017) which consisted of a $14.1 million increase in amortization expense, a $12.5 million increase in contingent consideration expense resulting from a change in the estimated fair value of our contingent consideration liabilities and a $19.4 million increase in other operating expenses.
Selling, general and administrative expenses for the nine months ended September 30, 2018 increased $173.4 million compared to the prior year period. The increase is primarily attributable to expenses incurred by our acquired businesses (primarily Neotract, which we acquired in October 2017) which consisted of a $47.4 million increase in amortization expense, a $50.0 million increase in contingent consideration expense resulting from a change in the estimated fair value of our contingent consideration liabilities and a $58.1 million increase in other operating expenses.
Research and development

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in millions)
Research and development | $ | 26.4 |  |  | $ | 21.2 |  |  | $ | 78.4 |  |  | $ | 59.3 |
Percentage of sales | 4.3 | % |  | 4.0 | % |  | 4.3 | % |  | 3.8 | %

The increase in research and development expenses for the three and nine months ended September 30, 2018 compared to the respective prior year periods primarily is attributable to expenses incurred in connection with our anesthesia and interventional urology product portfolios.
Restructuring and impairment charges

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in millions)
Restructuring and impairment charges (credits) | $ | 19.2 |  |  | $ | (0.1 | ) |  | $ | 77.6 |  |  | $ | 13.7 |

For the three and nine months ended September 30, 2018, we recorded $19.2 million and $77.6 million in restructuring and impairment charges; the charges for each period include $17.2 million of asset impairment charges related to our decision to abandon certain intellectual property and other assets associated with products that will be eliminated from our interventional product portfolio. Restructuring and impairment charges for the nine months ended September 30, 2018 also include employee termination benefits of $57.2 million recognized primarily in connection with our 2018 Footprint realignment plan.
For the three months ended October 1, 2017, we recorded $0.1 million in net restructuring credits, which primarily related to changes in estimates with respect to employee termination benefits. For the nine months ended October 1, 2017, we recorded $13.7 million in restructuring charges, which primarily related to termination benefits incurred in connection with the 2017 EMEA restructuring program and the 2017 Vascular Solutions integration program.
36

2018 Footprint realignment plan
On May 1, 2018, we initiated a restructuring plan involving the relocation of certain European manufacturing operations to existing lower-cost locations, the outsourcing of certain European distribution operations and related workforce reductions (the “2018 Footprint realignment plan"). These actions commenced in the second quarter 2018 and are expected to be substantially completed by the end of 2024.
We estimate that we will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2018 Footprint realignment plan of $102 million to $133 million, of which, we expect $55 million to $72 million to be incurred in 2018 and most of the balance to be incurred prior to the end of 2024. We estimate that $99 million to $127 million of these charges will result in future cash outlays, of which we expect $6 million to $8 million to be made in 2018 and most of the balance to be made by the end of 2024. Additionally, we expect to incur $19 million to $23 million in aggregate capital expenditures under the plan, of which, we expect up to $1 million to be incurred during 2018 and most of the balance to be incurred by the end of 2021.
We expect to begin realizing plan-related savings in 2018 and expect to achieve annual pre-tax savings of $25 million to $30 million once the plan is fully implemented.
Anticipated charges and pre-tax savings related to restructuring programs and other similar cost savings initiatives
In addition to the 2018 Footprint realignment plan, we have ongoing restructuring programs related to (i) the integration of Vascular Solutions into Teleflex; (ii) the centralization of certain administrative functions in our EMEA segment; (iii) the consolidation of our manufacturing operations (referred to as our 2018, 2016 and 2014 Footprint realignment plans); and (iv) other restructuring programs designed to improve operating efficiencies and reduce costs. See Note 5 to the condensed consolidated financial statements included in this report. We also have similar ongoing activities to relocate certain manufacturing operations within our OEM segment ("the OEM initiative") that do not meet the criteria for a restructuring program under applicable accounting guidance, but the activities should result in cost savings (we expect only minimal costs to be incurred). With respect to our restructuring programs and the OEM initiative, the table below summarizes (1) the estimated total restructuring and restructuring related charges and estimated annual pre-tax savings (including pre-tax savings related to the OEM initiative) once the programs are completed; (2) the restructuring and restructuring related charges incurred and estimated pre-tax savings realized through December 31, 2017; and (3) the restructuring and restructuring related charges expected to be incurred and estimated incremental pre-tax savings (including pre-tax savings related to the OEM initiative) estimated to be realized for these programs from January 1, 2018 through the anticipated completion dates.
Estimated charges and pre-tax savings are subject to change based on, among other things, the nature and timing of restructuring and similar activities, changes in the scope of restructuring programs and the OEM initiative, unanticipated expenditures and other developments, the effect of additional acquisitions or dispositions and other factors that were not reflected in the assumptions made by management in previously estimating restructuring and restructuring related charges and estimated pre-tax savings. Moreover, estimated pre-tax savings constituting efficiencies resulting from programs designed to reduce increased costs that otherwise would have resulted from business acquisitions involve, among other things, assumptions regarding the cost structure and integration of businesses that previously were not administered by our management, which are subject to a particularly high degree of risk and uncertainty. It is likely that estimates of charges and pre-tax savings will change from time to time, and the table below may reflect changes from amounts previously estimated. In addition, the table below does not include estimated charges and pre-tax savings related to completed programs. Estimated charges expected to be incurred in connection with the restructuring programs are described in more detail in Note 5 to the condensed consolidated financial statements included in this report.
As used in the following table, “pre-tax savings” includes (1) anticipated cost savings to be realized with respect to our historical expense items and (2) anticipated efficiencies to be realized with respect to increased costs that otherwise would have resulted from our acquisition of Vascular Solutions and Pyng Medical Corp. ("Pyng"), which we acquired in 2017.
37

| Ongoing restructuring programs and other similar cost savings initiatives
| Estimated Total |  | Through December 31, 2017 |  | Estimated Remaining from January 1, 2018 through December 31, 2024
| (Dollars in millions)
Restructuring charges | $111 - $126 |  | $42 |  | $69 - $84
Restructuring related charges (1) | 102 - 124 |  | 44 |  | 58 - 80
Total charges | $213 - $250 |  | $86 |  | $127 - $164
OEM initiative pre-tax savings | $6 - $7 |  | $— |  | $6 - $7
Pre-tax savings (2)(3) | $105 - $121 |  | $45 |  | $60 - $76
Total pre-tax savings | $111 - $128 |  | $45 |  | $66 - $83

(1) | Restructuring related charges principally constitute pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily consisting of costs to transfer manufacturing operations to the new location and project management costs, as well as a charge associated with our exit from facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Most of these charges (other than the tax charge) are expected to be recognized in costs of goods sold.

(2) | Approximately 65% of the pre-tax savings are expected to result in reductions to cost of goods sold. As previously disclosed, during 2016, in connection with our execution of the 2014 Footprint realignment plan, we implemented changes to medication delivery devices included in certain of our kits, which are expected to result in increased product costs (and therefore reduce the annual savings we anticipated at the inception of the plan). However, we also expect to achieve improved pricing on these kits that will offset the increased product costs. The improved pricing is expected to result in estimated annual increased revenues of $5 million to $6 million, which is not reflected in the table above. We realized a $1.0 million benefit resulting from this incremental pricing in 2017. Moreover, during the fourth quarter of 2017, we entered into an agreement with an alternate provider for the development and supply of a component to be included in certain kits sold by our Vascular North America and Anesthesia North America operating segments. The agreement will result in increased development costs, but is expected to reduce the cost of the component supply, once the supply becomes commercially available, as compared to the cost incurred with respect to our current suppliers. Therefore, we anticipate a net savings from the agreement, which is reflected in the table above.

(3) | While pre-tax savings address anticipated cost savings to be realized with respect to our historical expense items, they also reflect anticipated efficiencies to be realized with respect to increased costs that otherwise would have resulted from our acquisition of Vascular Solutions and Pyng, which we acquired in 2017. In this regard, the pre-tax savings are expected to result from the elimination of redundancies between our operations and Vascular Solutions’ and Pyng's operations, principally through the elimination of personnel redundancies.

Interest expense

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
| (Dollars in millions)
Interest expense | $ | 27.2 |  |  | $ | 21.3 |  |  | $ | 79.8 |  |  | $ | 58.9 |
Average interest rate on debt | 4.5 | % |  | 3.8 | % |  | 4.4 | % |  | 3.6 | %

The increase in interest expense for the three and nine months ended September 30, 2018 compared to the respective prior year periods was primarily due to an increase in average debt outstanding resulting from additional borrowings under our principal credit facility, as well as the November 2017 issuance of our 4.625% Senior Notes due 2027 ("2027 Notes"). The increase in interest expense was also the result of a higher average interest rate on our debt.
Taxes on income from continuing operations

| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | September 30, 2018 |  | October 1, 2017
Effective income tax rate | (2.3 | )% |  | 11.2 | % |  | 11.8 | % |  | 8.9 | %

38

The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The legislation significantly changed U.S. tax law by, among other things, permanently reducing corporate income tax rates from a maximum of 35% to 21%, effective January 1, 2018; implementing a territorial tax system, by generally providing for, among other things, a dividends received deduction on the foreign source portion of dividends received from a foreign corporation if specified conditions are met; and imposing a one-time repatriation tax on undistributed post-1986 foreign subsidiary earnings and profits, which are deemed repatriated for purposes of the tax. In addition, the TCJA imposes two new U.S. tax base erosion provisions: (1) the global intangible low-taxed income ("GILTI") provisions and (2) the base erosion and anti-abuse tax ("BEAT") provisions, which are explained in more detail in Note 13 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017.
In accordance with the applicable provisions of SEC Staff Accounting Bulletin No. 118, we included in our consolidated financial statements as of December 31, 2017 provisional amounts reflecting the tax impact related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities. During the third quarter, we recorded a $2.1 million tax benefit to adjust our initial provisional estimates for the TCJA in our provision for income taxes. The adjustment was specifically related to our initial estimate of the revaluation of certain deferred tax balances as a result of the reduced corporate income tax rate. To date, we have not made any other significant changes to our initial provisional estimates included in our consolidated financial statements as of December 31, 2017 and continue to evaluate the impact of the TCJA. Once our accounting for the income tax effects of the TCJA is complete, the amounts with respect to the income tax effects of the TCJA may differ from the provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions we have made, additional regulatory guidance that may be issued, and actions we may take as a result of the TCJA.
The effective income tax rate for the three and nine months ended September 30, 2018 was (2.3)% and 11.8%, respectively, and was 11.2% and 8.9% for the three and nine months ended October 1, 2017, respectively. The effective income tax rate for the three and nine months ended September 30, 2018 as compared to the prior year periods reflects impacts of the TCJA, including the benefit of a lower U.S. corporate tax rate of 21.0% from the enactment of the TCJA, partially offset by a tax cost associated with GILTI. In addition, the effective tax rate for the three and nine months ended September 30, 2018 includes a tax benefit associated with the asset impairment charge, as described in Note 5 to the consolidated condensed financial statements included in this report, excess tax benefits associated with share based payments, and a non-deductible contingent consideration expense recognized in connection with an increase in the fair value of the NeoTract contingent consideration liability. The effective income tax rate for the nine months ended September 30, 2018 as compared to the prior year period reflects non-deductible termination benefits and other costs incurred in connection with the 2018 Footprint realignment plan. The effective tax rate for the nine months ended October 1, 2017 reflected a tax benefit associated with costs incurred in connection with the Vascular Solutions acquisition.
39

Segment Financial Information

Segment net revenues |  |  |  |  |  |  |  |  |  |  |
| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | % Increase/ (Decrease) |  | September 30, 2018 |  | October 1, 2017 |  | % Increase/ (Decrease)
| (Dollars in millions) |  |  |  | (Dollars in millions) |  |
Vascular North America | $ | 80.7 |  |  | $ | 75.1 |  |  | 7.5 |  |  | $ | 243.8 |  |  | $ | 232.9 |  |  | 4.7 |
Interventional North America | 66.7 |  |  | 60.7 |  |  | 9.9 |  |  | 191.9 |  |  | 158.9 |  |  | 20.7 |
Anesthesia North America | 53.2 |  |  | 50.8 |  |  | 4.6 |  |  | 154.3 |  |  | 148.1 |  |  | 4.1 |
Surgical North America | 42.5 |  |  | 40.8 |  |  | 4.3 |  |  | 123.9 |  |  | 131.5 |  |  | (5.7 | )
EMEA | 139.6 |  |  | 137.0 |  |  | 1.8 |  |  | 452.9 |  |  | 409.1 |  |  | 10.7 |
Asia | 76.5 |  |  | 74.2 |  |  | 3.2 |  |  | 207.1 |  |  | 190.4 |  |  | 8.8 |
OEM | 54.9 |  |  | 48.6 |  |  | 12.9 |  |  | 153.3 |  |  | 137.1 |  |  | 11.8 |
All other | 95.6 |  |  | 47.5 |  |  | 101.4 |  |  | 279.6 |  |  | 143.2 |  |  | 95.2 |
Segment net revenues | $ | 609.7 |  |  | $ | 534.7 |  |  | 14.0 |  |  | $ | 1,806.8 |  |  | $ | 1,551.2 |  |  | 16.5 |
Segment operating profit |  |  |  |  |  |  |  |  |  |  |
| Three Months Ended |  | Nine Months Ended
| September 30, 2018 |  | October 1, 2017 |  | % Increase/ (Decrease) |  | September 30, 2018 |  | October 1, 2017 |  | % Increase/ (Decrease)
| (Dollars in millions) |  |  |  |  | (Dollars in millions) |  |
Vascular North America | $ | 24.3 |  |  | $ | 17.8 |  |  | 36.4 |  |  | $ | 73.6 |  |  | $ | 54.6 |  |  | 34.9 |
Interventional North America | 17.2 |  |  | 12.5 |  |  | 37.3 |  |  | 47.9 |  |  | 13.3 |  |  | 260.1 |
Anesthesia North America | 16.8 |  |  | 15.1 |  |  | 11.4 |  |  | 48.8 |  |  | 48.4 |  |  | 0.9 |
Surgical North America | 15.9 |  |  | 13.6 |  |  | 16.8 |  |  | 47.7 |  |  | 47.3 |  |  | 0.9 |
EMEA | 21.9 |  |  | 24.2 |  |  | (9.4 | ) |  | 80.2 |  |  | 69.1 |  |  | 16.1 |
Asia | 20.9 |  |  | 20.4 |  |  | 2.0 |  |  | 55.0 |  |  | 50.3 |  |  | 9.3 |
OEM | 15.0 |  |  | 12.3 |  |  | 22.8 |  |  | 37.6 |  |  | 31.7 |  |  | 18.6 |
All other | (5.6 | ) |  | 7.3 |  |  | (176.6 | ) |  | (43.2 | ) |  | 25.6 |  |  | (268.4 | )
Segment operating profit (1) | $ | 126.4 |  |  | $ | 123.2 |  |  | 2.6 |  |  | $ | 347.6 |  |  | $ | 340.3 |  |  | 2.1 |

(1) | See Note 14 to our condensed consolidated financial statements included in this report for a reconciliation of segment operating profit to our condensed consolidated income from continuing operations before interest, loss on extinguishment of debt and taxes.

Comparison of the three and nine months ended September 30, 2018 and October 1, 2017
Vascular North America
Vascular North America net revenues for the three months ended September 30, 2018 increased $5.6 million, or 7.5%, compared to the prior year period. The increase is primarily attributable to a $4.0 million increase in sales volumes of existing products and an increase in new product sales.
Vascular North America net revenues for the nine months ended September 30, 2018 increased $10.9 million, or 4.7%, compared to the prior year period. The increase is primarily attributable to a $4.5 million increase in new product sales, a $4.4 million increase in sales volumes of existing products and price increases.
Vascular North America operating profit for the three months ended September 30, 2018 increased $6.5 million, or 36.4%, compared to the prior year period. The increase is primarily attributable to an increase in gross profit resulting from higher sales volumes and lower manufacturing costs as well as lower general and administrative expenses.
Vascular North America operating profit for the nine months ended September 30, 2018 increased $19.0 million, or 34.9%, compared to the prior year period. The increase is primarily attributable to an increase in gross profit resulting from lower manufacturing costs, higher sales volumes and new product sales as well as lower operating expenses.
40

Interventional North America
Interventional North America net revenues for the three months ended September 30, 2018 increased $6.0 million, or 9.9%, compared to the prior year period. The increase is primarily attributable a $2.7 million increase in sales volumes of existing products and a $1.6 million increase in new product sales.
Interventional North America net revenues for the nine months ended September 30, 2018 increased $33.0 million, or 20.7%, compared to the prior year period. The increase is primarily attributable to net revenues of $19.6 million generated by acquired businesses (primarily Vascular Solutions) as well as increases in sales volumes of existing products and new product sales.
Interventional North America operating profit for the three months ended September 30, 2018 increased $4.7 million, or 37.3%, compared to the prior year period. The increase is primarily attributable to an increase in gross profit resulting from lower manufacturing costs and higher sales volumes partially offset by unfavorable product mix.
Interventional North America operating profit for the nine months ended September 30, 2018 increased $34.6 million, or 260.1%, compared to the prior year period. The increase is primarily attributable to gross profit generated by acquired businesses (primarily Vascular Solutions). In addition, during the nine months ended October 1, 2017, Interventional North America gross profit reflected the adverse effect of the step-up in carrying value of inventory recognized in connection with the Vascular Solutions acquisition.
Anesthesia North America
Anesthesia North America net revenues for the three months ended September 30, 2018 increased $2.4 million, or 4.6%, compared to the prior year period. The increase in net revenues is primarily attributable to a $1.7 million increase in sales volumes of existing products and a $1.5 million increase in new product sales partially offset by price decreases.
Anesthesia North America net revenues for the nine months ended September 30, 2018 increased $6.2 million, or 4.1%, compared to the prior year period. The increase is primarily attributable to a $4.1 million increase in new product sales and a $3.5 million increase in sales volumes of existing products partially offset by price decreases.
Anesthesia North America operating profit for the three months ended September 30, 2018 increased $1.7 million, or 11.4%, compared to the prior year period. The increase in operating profit is primarily attributable to the increase in gross profit resulting from higher sales volumes, new product sales and favorable fluctuations in foreign currency exchange rates partially offset by higher research and development costs.
Anesthesia North America operating profit for the nine months ended September 30, 2018 increased $0.4 million, or 0.9%, compared to the prior year period. The increase in operating profit is primarily attributable to an increase in gross profit partially offset by the prior year period operating profit reflects a favorable ruling in a lawsuit involving an insurance provider, which resulted in a $6.4 million gain.
Surgical North America
Surgical North America net revenues for the three months ended September 30, 2018 increased $1.7 million or 4.3% compared to the corresponding prior year period. The increase is primarily attributable to a $1.2 million increase in sales volumes of existing products and new product sales.
Surgical North America net revenues for the nine months ended September 30, 2018 decreased $7.6 million, or 5.7%, compared to the prior year period. The decrease is primarily attributable to a $9.3 million decrease in sales volumes of existing products partially offset by an increase in new product sales.
Surgical North America operating profit for the three months ended September 30, 2018 increased $2.3 million, or 16.8% compared to the prior year period. The increase was primarily attributable to lower operating expenses and to a lesser extent an increase in gross profit.
Surgical North America operating profit for the nine months ended September 30, 2018 increased $0.4 million, or 0.9% compared to the prior year period. The increase was primarily attributable to lower operating expenses, including a benefit resulting from a decrease in the estimated fair value of our contingent consideration liabilities, largely offset by a decrease in gross profit resulting from decreased sales volumes and unfavorable fluctuations in foreign currency exchange rates.
41

EMEA
EMEA net revenues for the three months ended September 30, 2018 increased $2.6 million, or 1.8%, compared to the prior year period. The increase is primarily attributable to price increases of $2.9 million and an increase in new product sales, partially offset by a decrease in sales volumes of existing products.
EMEA net revenues for the nine months ended September 30, 2018 increased $43.8 million, or 10.7%, compared to the prior year period. The increase is primarily attributable to favorable fluctuations in foreign currency exchange rates of $28.6 million and price increases.
EMEA operating profit for the three months ended September 30, 2018 decreased $2.3 million, or 9.4%, compared to the prior year period. The decrease is primarily attributable to higher operating expenses, including selling and amortization expenses, and unfavorable fluctuations in foreign currency exchange rates. These factors were partially offset by an increase in gross profit resulting from price increases.
EMEA operating profit for the nine months ended September 30, 2018 increased $11.1 million, or 16.1%, compared to the prior year period. The increase is primarily attributable to an increase in gross profit resulting from favorable fluctuations in foreign currency exchange rates and price increases partially offset by higher operating costs, including selling and amortization expenses.
Asia
Asia net revenues for the three months ended September 30, 2018 increased $2.3 million, or 3.2%, compared to the prior year period. The increase is primarily attributable to a $2.1 million increase in sales volumes of existing products and a $1.8 million increase in new product sales, partially offset by unfavorable fluctuations in foreign currency exchange rates of $2.4 million.
Asia net revenues for the nine months ended September 30, 2018 increased $16.7 million, or 8.8%, compared to the prior year period. The increase is primarily attributable to a $6.6 million increase in sales volumes of existing products, an increase in new product sales of $4.5 million, net revenues generated by acquired businesses and favorable fluctuations in foreign currency exchange rates.
Asia operating profit for the three months ended September 30, 2018 increased $0.5 million, or 2.0%, compared to the prior year period. The increase was primarily attributable to lower operating expenses, partially offset by a decrease in gross profit resulting from an unfavorable product mix.
Asia operating profit for the nine months ended September 30, 2018 increased $4.7 million, or 9.3%, compared to the prior year period. The increase was primarily attributable to an increase in gross profit resulting from favorable fluctuations in foreign currency exchange rates as well as increases in sales volumes partially offset by higher operating costs.
OEM
OEM net revenues for the three and nine months ended September 30, 2018 increased $6.3 million, or 12.9%, and $16.2 million, or 11.8%, respectively, compared to the respective prior year periods. The increases are primarily attributable to increases in sales volumes of existing products and acceleration in the timing of revenue recognition resulting from the adoption of new accounting guidance.
OEM operating profit for the three months ended September 30, 2018 increased $2.7 million, or 22.8%, compared to the prior year period. The increase is primarily attributable to an increase in gross profit resulting from higher sales volumes and favorable product mix partially offset by higher manufacturing costs.
OEM operating profit for the nine months ended September 30, 2018 increased $5.9 million, or 18.6%, compared to the prior year period. The increase is primarily attributable to an increase in gross profit resulting from higher sales volumes partially offset by higher manufacturing costs and lower general and administrative costs.
All Other
Net revenues for our other operating segments increased $48.1 million, or 101.4% and $136.4 million, or 95.2%, for the three and nine months ended September 30, 2018, respectively, compared to the respective prior year periods. The increases are primarily attributable to net revenues generated by NeoTract.
Operating profit for our other operating segments decreased $12.9 million or 176.6% and $68.8 million, or 268.4%, for the three and nine months ended September 30, 2018 compared to the respective prior year periods. The decreases are primarily attributable to expense resulting from an increase in the estimated fair value of our contingent
42

consideration liabilities and amortization expense, both of which are primarily related to the NeoTract acquisition, partially offset by an increase in gross profit resulting from NeoTract sales.
Liquidity and Capital Resources
We believe our cash flow from operations, available cash and cash equivalents and borrowings under our revolving credit facility will enable us to fund our operating requirements, capital expenditures and debt obligations for the next 12 months and the foreseeable future. We have net cash provided by United States based operating activities as well as non-United States sources of cash available to help fund our debt service requirements in the United States. We manage our worldwide cash requirements by monitoring the funds available among our subsidiaries and determining the extent to which we can access those funds on a cost effective basis.
The TCJA significantly changed U.S. tax law by, among other things, imposing a one-time repatriation tax on undistributed post-1986 earnings and profits of foreign subsidiaries. Previously, we were not taxed in the U.S. on certain foreign earnings unless and until they were repatriated to the U.S. Under the TCJA, we will have to pay $154.0 million over eight years for the deemed repatriation of these foreign earnings, regardless of whether such earnings are actually repatriated. As a result of the repatriation tax provisions of the TCJA, we anticipate that, generally, we will be able to access cash located at our foreign subsidiaries without incurring any additional U.S. federal income tax liabilities. We are not aware of any other restrictions on repatriation of these funds and, subject to cash payment of additional foreign withholding taxes, these funds could be repatriated, if necessary.
On October 4, 2018, we executed cross-currency swap agreements with six financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the swap agreements, we notionally exchanged $500 million at an interest rate of 4.625% for €433.9 million at an interest rate of 1.942%. The swap agreements, which expire on October 4, 2023, are designated as net investment hedges and require an exchange of the notional amounts upon expiration or the earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement. As a result, we may be required to pay (or be entitled to receive) an amount equal to the difference, on the expiration or earlier termination date, between the U.S. dollar equivalent of the €433.9 million notional amount and the $500 million notional amount. The swap agreements entail risk that the counterparties will not fulfill their obligations under the agreements. However, we believe the risk is reduced because we have entered into separate agreements with six different counterparties, all of whom are large, well-established financial institutions. Based on the U.S. dollar to euro currency exchange rate in effect on October 4, 2018, and assuming exchange rates remain constant throughout the five year term of the swap agreements, we would realize a reduction in annual cash interest expense of $13.4 million. See Part I, Item 3, “Quantitative and Qualitative Disclosure About Market Risk” in this report for additional information.
To date, we have not experienced significant payment defaults by our customers, and we have sufficient lending commitments in place to enable us to fund our anticipated additional operating needs. However, although there have been recent improvements in certain countries, global financial markets remain volatile and the global credit markets are constrained, which creates a risk that our customers and suppliers may be unable to access liquidity. Consequently, we continue to monitor our credit risk, particularly with respect to customers in Greece, Italy, Portugal and Spain, and consider other mitigation strategies. As of September 30, 2018 and December 31, 2017, our net trade accounts receivable from publicly funded hospitals in Italy, Spain, Portugal and Greece were $24.4 million and $24.7 million, respectively. As of September 30, 2018 and December 31, 2017, our net trade accounts receivable from customers in these countries were approximately 14.1% and 15.0%, respectively of our consolidated net trade accounts receivable. For the nine months ended September 30, 2018 and October 1, 2017, net revenues from customers in these countries were 6.0% and 6.2%of total net revenues, respectively, and average days that current and long-term trade accounts receivable were outstanding were 151 days and 159 days, respectively. If economic conditions in these countries deteriorate, we may experience significant credit losses related to the public hospital systems in these countries. Moreover, if global economic conditions generally deteriorate, we may experience further delays in customer payments, reductions in our customers’ purchases and higher credit losses, which could have a material adverse effect on our results of operations and cash flows in 2018 and future years.
Cash Flows
Cash flows from operating activities from continuing operations provided net cash of approximately $302.9 million for the nine months ended September 30, 2018 as compared to $319.7 million for the nine months ended October 1, 2017. The $16.8 million decrease is attributable to the net unfavorable impact of changes in working capital partially offset by favorable operating results. The net unfavorable impact from changes in working capital was due to a
43

net decrease in income taxes payable and a net increase in accounts receivable partially offset by an increase in accounts payable, accrued expenses and other liabilities.
The decrease in income taxes payable for the nine months ended September 30, 2018 was $43.2 million compared to an increase of $3.8 million for nine months ended October 1, 2017. The decrease in income taxes payable was the result of higher payments during the first nine months of 2018 as compared to the same period in 2017. The increase in accounts receivable for the nine months ended September 30, 2018 was $29.8 million compared to a decrease of $6.4 million for nine months ended October 1, 2017. The net increase in accounts receivable is attributable to higher net revenues during the first nine months of 2018. In addition, in the first quarter of 2017, we sold $16.0 million of outstanding receivables related to sales of our products to public hospitals in Italy. The increase in accounts payable, accrued expenses and other liabilities for the nine months ended September 30, 2018 was $54.6 million compared to an increase of $24.1 million for nine months ended October 1, 2017. The increase is attributable to increased restructuring activity primarily related to the 2018 Footprint realignment plan partially offset by lower payroll related accruals.
Net cash used in investing activities from continuing operations was $78.3 million for the nine months ended September 30, 2018, which includes a cash outflow for capital expenditures of $55.8 million and acquisition payments of $22.6 million principally related to our acquisition of assets from QT Vascular.
Net cash used in financing activities from continuing operations was $199.7 million for the nine months ended September 30, 2018, which includes borrowing repayments of $98.5 million, contingent consideration payments of $73.2 million and dividend payments of $46.5 million, partially offset by proceeds from share based compensation and related tax benefits of $18.7 million.
Borrowings
The credit agreement relating to our revolving credit facility and a term loan used to fund a portion of the consideration we paid to acquire Vascular Solutions (the “Credit Agreement”) and the indentures under which we issued our 5.25% Senior Notes due 2024 (the “2024 Notes”) and 4.875% Senior Notes due 2026 (the "2026 Notes") contain covenants that, among other things, limit or restrict our ability, and the ability of our subsidiaries, to incur additional debt or issue preferred stock or other disqualified stock; create liens; pay dividends, make investments or make other restricted payments; sell assets; merge, consolidate, sell or otherwise dispose of all or substantially all of our assets; or enter into transactions with our affiliates. The indenture with respect to our 2027 Notes contains covenants that, among other things, limit or restrict our ability, and the ability of our subsidiaries, to create liens; consolidate, merge or dispose of certain assets; and enter into sale leaseback transactions. Additionally, the Credit Agreement contains financial covenants that require us to maintain a consolidated total leverage ratio (generally, Consolidated Total Funded Indebtedness, as defined in the Credit Agreement, on the date of determination to Consolidated EBITDA, as defined in the Credit Agreement, for the four most recent fiscal quarters ending on or preceding the date of determination) of not more than 4.50 to 1.00, and a consolidated senior secured leverage ratio (generally, Consolidated Senior Secured Funded Indebtedness, as defined in the Credit Agreement, on the date of determination to Consolidated EBITDA for the four most recent fiscal quarters ending on or preceding the date of determination) of not more than 3.50 to 1.00. The Company is further required to maintain a consolidated interest coverage ratio (generally, Consolidated EBITDA for the four most recent fiscal quarters ending on or preceding the date of determination to Consolidated Interest Expense, as defined in the Credit Agreement, paid in cash for such period) of not less than 3.50 to 1.00.
As of September 30, 2018, we were in compliance with these requirements. The obligations under the Credit Agreement, the 2024 Notes, the 2026 Notes and the 2027 Notes are guaranteed (subject to certain exceptions) by substantially all of our material domestic subsidiaries, and the obligations under the Credit Agreement are (subject to certain exceptions and limitations) secured by a lien on substantially all of the assets owned by us and each guarantor.
Critical Accounting Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and assumptions.
In our Annual Report on Form 10-K for the year ended December 31, 2017, we provided disclosure regarding our critical accounting estimates, which are reflective of significant judgments and uncertainties, are important to the
44

presentation of our financial condition and results of operations and could potentially result in materially different results under different assumptions and conditions.
New Accounting Standards
See Note 2 to the condensed consolidated financial statements included in this report for a discussion of recently issued accounting guidance, including estimated effects, if any, of adoption of the guidance on our financial statements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
On October 4, 2018, we entered into cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the swap agreements, we notionally exchanged $500.0 million at an annual interest rate of 4.625% for €433.9 million at an annual interest rate of 1.942%. The swap agreements, which expire on October 4, 2023, are designated as net investment hedges and require an exchange of the notional amounts upon expiration or earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement.
The interest component of the swap agreements will affect the interest expense recognized within our statement of operations. Based on the U.S. dollar to euro currency exchange rate in effect on October 4, 2018, and assuming the exchange rates remain constant throughout the five year term of the cross-currency swap agreements, we would realize an annual pre-tax net benefit (i.e., a reduction in interest expense as a result of the swap agreements) of $13.4 million, or a total of $67.0 million over the five year term of the swap agreements. A 10% increase or decrease in the U.S. dollar to euro currency exchange rate in effect on October 4, 2018 would result in a change to the annual pre-tax net benefit of approximately $1.0 million.
As described in Note 2 to the condensed consolidated financial statements included in this report, the Financial Accounting Standards Board (“FASB”) issued guidance in August 2017 with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. As a result of our early adoption of the FASB guidance, and because the swap agreements are designated as net investment hedges, changes in the fair value of the cross-currency swap agreements will be recognized as a component of “Foreign currency translation continuing operations adjustments, net of tax” within “Other comprehensive (loss) income, net of tax” in the consolidated statement of comprehensive income. In this regard, a favorable foreign currency change in the designated investment value of our foreign subsidiaries that use euros as their functional currency generally will be offset by an unfavorable foreign currency change in the swap agreements, and vice versa. At October 4, 2018, a 10% fluctuation in the U.S. dollar to euro currency exchange rate would have an approximately $50 million impact on the fair value of the notional amount of the cross-currency swap agreements and an offsetting $50 million impact on the designated net investment value of the foreign subsidiaries. In addition, in the event of a significant decline in the U.S. dollar to euro exchange rate, our payment obligations to the counterparties could have a material adverse effect on our cash flows. In this regard, if, at the expiration or earlier termination of the swap agreements, the U.S. dollar to euro currency exchange rate has declined by 10% from the rate in effect at October 4, 2018, we would be required to pay approximately $50 million to the counterparties.
The swap agreements entail risk that the counterparties will not fulfill their obligations under the agreements. However, we believe the risk is reduced because we have entered into separate agreements with six different counterparties, all of whom are large, well-established financial institutions.
Except as set forth above, there have been no material changes to the information set forth in Part II, Item 7A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
Item 4. Controls and Procedures
(a) Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial
45

Officer, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management’s assessment of disclosure controls and procedures excluded consideration of NeoTract’s internal control over financial reporting. NeoTract was acquired during the fourth quarter of 2017 and the exclusion is consistent with guidance provided by the staff of the Securities and Exchange Commission that an assessment of a recently acquired business may be omitted from management’s report on internal control over financial reporting for up to one year from the date of acquisition, subject to specified conditions. NeoTract's total assets (excluding goodwill and intangible assets) were $97.5 million as of September 30, 2018; its revenues for the three and nine months ended September 30, 2018 were $49.0 million and $139.0 million, respectively.
(b) Change in Internal Control over Financial Reporting
No change in our internal control over financial reporting occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
46

PART II — OTHER INFORMATION
Item 1. Legal Proceedings
We are party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability and product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of September 30, 2018 and December 31, 2017, we have accrued liabilities of approximately $1.8 million and $3.8 million, respectively, in connection with these matters, representing our best estimate of the cost within the range of estimated possible loss that will be incurred to resolve these matters. Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that the outcome of any outstanding lawsuits or claims is likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity.
Item 1A. Risk Factors
See the information set forth in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Except as set forth below, there have been no significant changes in risk factors for the quarter ended September 30, 2018.
Under our cross-currency swap agreements, a meaningful decline in the U.S. dollar to euro exchange rate could have a material adverse effect on our cash flows.
On October 4, 2018, we entered into cross-currency swap agreements with six different financial institutions to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the swap agreements, we notionally exchanged $500.0 million at an annual interest rate of 4.625% for €433.9 million at an annual interest rate of 1.942%. The swap agreements, which expire on October 4, 2023, require an exchange of the notional amounts between us and the counterparties upon expiration or earlier termination of the agreements. If, at the expiration or earlier termination of the swap agreements, the U.S. dollar to euro exchange rate has declined from the rate in effect on October 4, 2018, an amount equal to the excess of the U.S. dollar value of €433.9 million over $500.0 million will be paid to the counterparties (we and the counterparties have agreed to a net settlement with regard to the exchange of the notional amounts at the date of expiration or earlier termination of the agreements). In the event of a significant decline in the U.S. dollar to euro exchange rate, our payment obligations to the counterparties could have a material adverse effect on our cash flows. In this regard, if, at the expiration or earlier termination of the swap agreements, the U.S. dollar to euro currency exchange rate has declined by 10% from the rate in effect at October 4, 2018, we would be required to pay approximately $50 million in respect of the notional settlement to the counterparties.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Not applicable.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Not applicable.
47

Item 6. Exhibits
The following exhibits are filed as part of this report:

Exhibit No. |  |  |  | Description
31.1 |  | — |  | Certification of Chief Executive Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
31.2 |  | — |  | Certification of Chief Financial Officer, pursuant to Rule 13a–14(a) under the Securities Exchange Act of 1934.
32.1 |  | — |  | Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 |  | — |  | Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.1 |  | — |  | The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2018 and October 1, 2017; (ii) the Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2018 and October 1, 2017; (iii) the Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017; (iv) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and October 1, 2017; (v) the Condensed Consolidated Statements of Changes in Equity for the nine months ended September 30, 2018; and (vi) Notes to Condensed Consolidated Financial Statements.

_____________________________________________________
48

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|  | TELEFLEX INCORPORATED
|  | By: |  | /s/ Liam J. Kelly
|  |  |  | Liam J. Kelly President and Chief Executive Officer (Principal Executive Officer)
|  | By: |  | /s/ Thomas E. Powell
|  |  |  | Thomas E. Powell Executive Vice President and Chief Financial Officer (Principal Financial Officer)

Dated: November 1, 2018
49